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It is very challenging to develop peptide and protein drugs for treatment of brain diseases 
because it is difficult to deliver them to the brain due to the presence of the blood-brain barrier 
(BBB). Therefore, there is an urgent need to develop new and alternative methods to deliver these 
drugs to the brain for treatment of brain diseases. ADTC5 and HAV6 peptides were derived from 
the binding sequence of the EC1 domain of E-cadherin protein, and these peptides can enhance 
the in vivo brain delivery of various molecules through the paracellular pathway of the BBB. 
Therefore, the overall goal of this project was to evaluate the activity of current and new cadherin 
cyclic peptides to enhance the in vivo brain delivery of peptides and proteins in rats and mice. 
The first goal of this project was to evaluate the activity of cadherin peptides (e.g., HAV6, 
HAV4, cHAVc3, and ADTC5) in delivering peptides (e.g., cIBR and cLABL) and 65 kDa 
galbumin protein to mouse and rat brains. The brain depositions of peptides and proteins were 
detected using near IR fluorescence (NIRF) imaging, magnetic resonance imaging (MRI), and 
mass spectrometry. The brain delivery of unlabeled cIBR7 peptide into rat brains was done to 
confirm that the intact molecule could be detected in the brain. An efficient extraction method was 
developed to isolate cIBR7 and ADTC5 from the brain tissue. A novel LC/MS/MS method was 
developed and validated to quantify cIBR7, an internal standard, and ADTC5 in brain after in vivo 
delivery. Detection was performed using triple quadrupole tandem mass spectrometry and a 
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multiple reaction monitoring technique. Our results showed a fourfold increase (p = 0.013) in the 
amount of intact cIBR7 in the brain when it was delivered using ADTC5 compared to cIBR7 alone. 
The second goal was to compare the activity of ADTC5 and HAV6 peptides in delivering 
various sized proteins, including IRdye800cw-labeled-lysozyme (15 kDa), albumin (65 kDa), IgG 
mAb (150 kDa), and fibronectin (220 kDa) into mouse brains. In addition, a quantitative NIRF 
imaging method was developed to determine brain depositions of these proteins. The results 
showed that ADTC5 peptide significantly enhanced brain delivery of lysozyme, albumin, and IgG 
mAb compared to controls; however, no enhancement was observed for fibronectin. HAV6 
peptide could enhance the brain delivery of lysozyme, but not the other proteins.  
The third goal was to design and synthesize new cyclic peptides for better modulation of the 
BBB. An N-to-C terminal cyclization method was utilized to improve the plasma stability and 
activity to modulate the BBB of the peptide. Linear and cyclic ADTHAV peptides were designed 
by combining the sequences of ADTC5 and HAV6. Cyclic HAVN1 and HAVN2 peptides were 
designed as N-to-C terminal cyclic derivatives of linear HAV6 peptide as new BBB modulator 
peptides. Binding properties of cyclic ADTHAV and ADTC5 peptides to the EC1 domain of E-
cadherin were determined using surface plasmon resonance (SPR), and ADTHAV was found to 
have higher binding affinity (Kd = 0.114 µM) than ADTC5 (Kd = 26.8 µM). The in vivo activities 
of these peptides to deliver an IRdye800cw-labeled IgG mAb into the brain were qualitatively and 
quantitatively determined using NIRF imaging. Cyclic HAVN1 and HAVN2 peptides enhanced 
brain delivery of IgG mAb compared to HAV6 peptide. Cyclic and linear ADTHAV as well as 
ADTC5 peptides enhanced brain delivery of IgG mAb. There seems to be a trend that cyclic 
ADTHAV peptide has better activity than linear ADTHAV under the current conditions (p = 0.07). 
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Overall, these three studies support the potential use of cadherin peptides in transiently modulating 
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Peptides have been successfully developed as therapeutic and diagnostic agents because of 
their selectivity to bind the respective target receptors.1-3  Currently, there are more than 60 peptide 
drugs approved by the US Food and Drug Administration (FDA). Thus, development of peptide 
drugs has increased significantly in the past decades and, as of today, approximately 140 peptides 
are in clinical trials as potential drugs. In addition, more than 500 therapeutic peptides are in 
preclinical development.3 Available peptide drugs which include oxytocin, calcitonin, octreotide, 
and exenatide are being used to treat various conditions. Some bioactive peptides have been 
derived from endogenous substances; however, some peptides were derived from truncation of the 
active region(s) of the parent proteins. For example, opioid peptides such as enkephalins, 
endorphins, and dynorphins that are found in the brain have been used as drugs. Oxytocin, an 
endogenous hormone released by the posterior pituitary, is a cyclic peptide synthesized in the 
paraventricular nucleus of the hypothalamus.4 Oxytocin and its analogs work as neurotransmitters 
in the brain to facilitate breastfeeding, induce labor, and treat postpartum hemorrhage. Calcitonin 
peptide is a hormone produced by the thyroid gland to control calcium and potassium levels in 
blood. A synthetic salmon-calcitonin peptide has been used to treat osteoporosis; this peptide was 
first developed as a nasal spray.5 Tumors can be treated by octreotide, which inhibits the release 
of growth hormones6. Type-2 diabetes is treated successfully with exenatide (Table 1.1), which is 
a derivative of a glucagon-like peptide-1 agonist (GLP-1; Table 1.1).7  Exenatide was developed 
to increase the in vivo half-life because GLP-1 was ineffective in clinical trials for diabetes 
treatment due to its short half-life. Exenatide binds to GLP-1 receptor and regulates glucose 
metabolism and insulin secretion. Both GLP-1 and glucose-dependent insulinotropic peptide (GIP) 
17 
 
hormones are produced upon ingestion of food to stimulate insulin secretion; however, only GLP-
1 causes insulin secretion in a diabetic state.  
Bioactive peptides can also be derived from the active region(s) of large functional proteins. 
One example is “Arg-Gly-Asp” (RGD), which is derived from the sequence of extracellular matrix 
(ECM) proteins such as fibronectin, fibrinogen, vitronectin, von Willebrand factor, laminin, and 
collagen.8 RGD sequence on the ECM is recognized by various integrin receptors on the cell 
surface for cell adhesion to ECM. The ECM-integrin binding is essential in various disease 
processes such as thrombosis, angiogenesis and tumor metastasis.9 In thrombosis, the process of 
vascular blood clotting prevents the normal blood flow from the heart, which involves platelet 
aggregation. Platelet aggregation results from interactions of fibrinogen and platelets, which are 
mediated by recognition of RGD sequences on the - and -subunits of fibrinogen by gpIIb/IIIa 
integrin receptors on platelet surfaces.10 Therefore, RGD peptides (e.g., integrilin or eptifibatide) 
and peptidomimetics (e.g., aggrastat or tirofiban) have been used as antithrombic agents in the 
clinic. Integrilin and aggrastat are selective and potent ligands for gpIIb/IIIa receptors, blocking 
platelet aggregation during thrombosis. Angiogenesis in solid tumors can be inhibited by RGD 
peptides (Table 1.1), which are designed to bind to cell-surface V3 and V5 integrins that are 
overexpressed during tumor angiogenesis.11 Other cell adhesion peptides, such as those derived 
from intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 
(LFA-1) receptors, have been shown to inhibit T-cell adhesion by adhesion to epithelial and 




Table 1.1 Peptide Names and Sequences 
Peptide  Sequence 
Exenatide HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 
GLP-1 HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR - NH2 
ALOS4 Cyclo1,9(CSSAGSLFC) 
RGD-1  Cyclo(RGDyK) 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
Penetratin RQIKIWFQNRRMKWKK  
PAF-26  RKKWFW 
Octreotide Cyclo2,7(fCFwKTCT) 
GnRH-1 EHWSYkLRPG-NH2 
GnRH-2  EHWSHkWYPG-NH2 
GnRH-3 EHWSHDWKPG-NH2 
pHLIP AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG 










PEGA  Cyclo1,10(CPGEPEGAGC) 
A54  AGKGTPSLETTP 








OCC2  GVNPQAQMSSGYYYSPLLAMC(Acm)SQAYGSTYLNQYIYHYC(Acm)TVDPQE;  
Acm = Acetamido methyl 




HAV6  Ac-SHAVSS-NH2 
ADTC5  Cyclo1,7(CDTPPVC) 
cIBR7 Cyclo1,8(CPRGGSVC) 
cLABL Cyclo1,12(PenITDGEATDSGC) 






In addition to their use as drugs, bioactive peptides have been used as targeting moieties for 
the delivery of drug payloads (e.g., anticancer and anti-inflammatory) to specific types of cells in 
tissues and, ultimately, to reduce their adverse side effects. Some of these peptides are internalized 
by their respective receptors into cells via a receptor-mediated endocytosis process. Others have 
been conjugated to drug-loaded nanoparticles for specific delivery to corresponding cell targets of 
the peptide. Receptor selective peptides were also investigated as diagnostic agents by conjugating 
them to dyes, radioisotopes, or magnetic resonance imaging (MRI) contrast agents. 
The ultimate goal of targeted drug delivery is to direct a drug to diseased cells or organs (e.g., 
cancer cells), while avoiding normal cells. This results in a drug construct with lower side effects 
than the free form of its parent drug. This chapter describes the roles of peptides in drug delivery, 
including the use of peptides as (a) peptide-drug and peptide-particle conjugates for targeting 
molecules to a specific type of cells and (b) modulators of biological barriers for improving the 
oral and brain delivery of drugs and diagnostic agents.  
1.2 Peptide-Drug Conjugates for Targeted Drug Delivery 
Drug targeting methods are normally explored to reduce side effects by directing toxic drugs 
to cells involved in disease states, leaving normal cells minimally affected. Conjugation of the 
drug to its peptide carrier (targeting agent) can be done directly or through a chemical linker. Thus, 
as a peptide carrier selectively binds to a specific receptor on the surface of targeted cells (i.e., 
cancer cells), it carries along the drug or diagnostic molecule with it. As an example, cancer cells 
have a certain upregulated receptor(s) (e.g., HER-2, EGFR) compared to normal cells. These 
upregulated receptors become distinguishing and exploitable features to selectively direct 
populations of conjugated drug molecules into cancer cells over normal cells. Binding of the 
conjugate to the target receptor is followed by cellular uptake of the ligand-receptor complex into 
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the early endosomes via receptor-mediated endocytosis.13 From the endosomes, the conjugate 
reaches the lysosomes where the drug is released as a result of lowered pH and/or enzyme 
degradation in the lysosomes. The rate of release of the drug can be controlled by designing the 
appropriate linker between the drug and the peptide.13-15 This method has been successfully applied 
in antibody-drug conjugates such as Adcetris® and Kadcycla® to treat cancer patients.15, 16 Peptides 
are smaller than proteins and can rapidly synthesized using solid-phase methods. Unlike proteins, 
most peptides have only primary and secondary structures. Thus, most peptides do not suffer as 
much from physical instability as do proteins, which often leads to the formation of aggregates 
that generate immunogenicity. Due to their small size, peptide-drug conjugates are potentially less 
immunogenic than protein-drug conjugates. Although their formulation remains challenging, 
peptide conjugate formulation is usually less complicated than that of protein-drug conjugates. 
In designing a peptide-drug conjugate, a functional group (i.e., amine, carboxylic acid, alcohol, 
or thiol) within the structure of the drug can be used to link the drug directly to a targeting peptide’s 
N- or C-termini, or a side-chain functional group of the Lys, Asp, Glu, Ser, Thr, or Cys residue(s) 
on the peptide. This direct drug-peptide linkage may be in the form of an amide, ester, or thioether 
bond. In many cases, the drug may be conjugated to the peptide using a molecular linker (e.g., 
PEG, maleimido, etc.). Other than bridging drug and targeting components of the construct, the 
vital role of the linker is to provide a distance between the peptide and the drug, which is often 
crucial to the overall activity and potency of the construct. In one respect, ample distance between 
the drug and targeting-peptide components prevents interference (or steric hindrance) in binding 
to their respective receptors. This is because both drug and peptide have a molecular surface 
recognized by their respective receptors for biological activity. Normally, the conjugation is done 
at the functional group away from the bioactive region of the peptide or the drug. In addition, the 
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linker can be designed to control the release of the drug from the conjugate upon reaching the cell 
targets within the tissue. Premature release of the drug in the systemic or lymphatic circulation 
before reaching the respective target cells can be harmful and, ultimately, defeats the purpose of 
drug-targeting.  
1.2.1 Peptide-Drug Conjugates for Cancer Therapy and Diagnostics 
Chemotherapy remains the treatment of choice for cancer patients.17 Most chemotherapeutic 
agents are cytotoxic and kill not only cancer cells but also normal cells in the body. Some drugs 
have poor solubility, are highly toxic, or cannot cross the cancer cell membranes into the 
intracellular space. Most cancer cells eventually generate resistance to anticancer drugs after 
multiple treatments. One of the drug-resistance mechanisms is due to the overexpression of efflux 
pumps (i.e., Pgp, MRP, MDR1) that expel the anticancer drug from the cancer cell membranes. 
Therefore, there is a need to develop an alternative method to deliver drugs into cancer cells and 
overcome drug resistance by avoiding the efflux pumps. One way to increase drug penetration 
across cell membranes is by utilizing receptor-mediated endocytosis mechanisms. Thus, drugs 
have been conjugated to peptides, proteins, nanocarriers, carbon nanotubes, and dendrimers. As 
an example, paclitaxel (PTX), which is widely used to treat breast, ovarian, testicular, and cervical 
cancers, is known to have poor water solubility.18 Thus, conjugation to a targeting peptide via a 
polyethylene glycol (PEG) linker increases solubility and improves selectivity to target cancer 
cells. 
1.2.2 Cell Adhesion Peptides 
Cell adhesion peptides have been used to target drugs and radioisotopes for cancer treatments 
and diagnostics. RGD peptides are cell adhesion molecules that have been extensively explored as 
carriers in peptide-drug conjugates. Certain cyclic RGD peptides bind selectively to V3 and V5 
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integrin receptors, which are upregulated during angiogenesis in tumors. Thus, these selective 
cyclic RGD peptides have been used to deliver radioisotopes such as 18F, 99mTc, 125I, or 64Cu as 
cancer diagnostic agents. For example, 18F-containing galactose was incorporated to RGD-1 
peptide (Table 1.1) via an amide bond to the D-Lys side chain.19 The 18F-labeled conjugate binds 
selectively to upregulated V3 integrin receptors on tumor vasculature as observed by positron 
emission tomography (PET). Thus, the conjugate can be used as imaging tool to detect 
angiogenesis and tumor metastasis in vivo.19 The levels of V3 receptors on human tumor cells 
have been detected with 18F-labeled conjugates and observed using PET. It was found that the 
detected levels of V3 receptors were similar to those detected using immunohistochemistry.
20 
Accumulation of 18F-labeled RGD-1 peptide in human tumors showed intra- and inter-variability 
of conjugate accumulation due to different levels of V3 across different individuals.
19 The 
various levels of V3 found in humans can be used to predict populations of cancer patients most 
likely to respond to treatments with RGD-anticancer drug conjugates. RGD peptides have been 
used to selectively deliver the anticancer drugs doxorubicin (DOX)21 and PTX22 to cancer cells in 
vitro and in vivo. RGD-1-DOX conjugate suppressed the growth of breast cancer xenographs in 
mice better than DOX alone, suggesting that cyclic RGD peptide improves the targeting of DOX 
to breast cancer cells in vivo.21 
ALOS4 peptide (Table 1.1) is a non-RGD peptide that also binds to V3 integrin. The peptide 
was linked to camptothecin (CPT) and fluorescein isothiocyanate (FITC) via a GABA linker to 
give ALOS4-CPT and ALOS4-FITC, respectively.23 FACS analysis showed a strong binding of 
ALSO4-FITC to WM-266-4, a malignant melanoma cells. In vivo studies confirmed that tumor-
bearing WM-266-4 cells in mice intravenously administered with ALOS4-FITC showed 
accumulation of ALOS4-FITC specifically in tumors rather than organs as observed after 24 hours. 
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Next, ALOS4-CPT enhanced drug cytotoxicity to tumor cells better than CPT and other anticancer 
drugs. CPT activity has been known to be deactivated by the hydrolytic opening of a vital lactone 
ring in its structure. In contrast to its free form, the stability of this lactone ring is increased in the 
ALOS-4-CPT conjugate.23 At 10 M, CPT alone kills high percentages of both malignant WM-
266-4 and non-malignant HEK-293 tumor cells (human embryonic kidney cells) while ALOS4-
CPT kills 70% of malignant WM-266-4 cell compared to 30% of the non-malignant HEK-293 
cell. The activity of the conjugate is dose-dependent.23 These results affirm that ALOS4 selectively 
targets and delivers conjugates to malignant tumor cells.  
1.2.3 Cell-Penetrating Peptides 
Generally, most peptides cannot readily cross the cell membranes due to their physicochemical 
properties; however, cell-penetrating peptides (CPPs with 6–30 amino acids) are capable of 
crossing membranes and entering the cell’s cytoplasm.24 A detailed mechanism of the cellular 
uptake of CPPs is not well understood, but it may take place either by direct translocation or by 
endocytosis. The early CPPs identified were trans-activating transcriptional activator (TAT) 
peptides, derived from human immunodeficiency virus 1 (HIV-1), and antennapedia 
homeodomain protein of drosophila (pAntp).25 These long sequences have been reduced to 6–7 
amino acid peptides, which maintain similar cell penetrating behavior. CPPs have been used for 
cellular delivery of small drug molecules (i.e., doxorubicin, methotrexate and taxol), proteins, 
nucleic acids, and contrasting agents. Apart from the natural CPPs, synthetic and semi-synthetic 
CPPs, including the chimeric 27-aa transportan, penetratin, and PAF-26, were designed to 




1.2.4 Peptide Hormone for Drug Delivery 
Peptide hormones such as octreotide (OCT), gonadotrophin-releasing hormone (GnRH), and 
epidermal growth factor (EGF) peptides (Table 1.1) have been investigated for delivering drugs 
to cancer cells. GnRH receptors are overexpressed in malignant tumor of ovarian, breast, prostate 
cancers as part of the paracrine/autocrine regulatory system of malignant tumors.26-28 OCT and 
other somatostatin peptides bind to somatostatin receptors (STTRs) especially STTR2, which are 
upregulated in breast, cervical, colon, lung, ovarian cancers cells.29 OCT peptide has a long half-
life in systemic circulation with good tissue penetration due to its uptake by the STTR2 receptor. 
OCT has also been used for targeting radiotherapies.28 PTX-OCT conjugate was designed to 
improve the biological properties of PTX and overcome the issue of cancer resistance. Ovarian 
cancer is treated with PTX, but normally through multiple sessions/doses, often causing the 
emergence of drug resistance.30 Localization of OCT peptide after delivery has been monitored 
using FITC-labeled OCT peptide (FITC-OCT),  injected into nude mice bearing a xenografted 
tumor. Localization of FITC-OCT on the xenografted tumor confirmed abnormally high levels of 
STTR2 receptor expression in tumors. PTX-OCT also suppressed tumor growth in mice xenografts 
better than in those treated with free PTX, OCT, and mixtures of PTX + OCT.30 This result 
demonstrates the selectivity of PTX-OCT to tumor cells on the basis of high expression of STTR2. 
In addition, the conjugate downregulates the expression of multi drug resistance-1 (MDR1) 
protein. 
GnRH or LHRH peptides effectively deliver anticancer drugs such as DOX and CPT to cancer 
cells.31, 32 FITC-labeled GnRH analogues have been used to compare targeting efficiencies of 
GnRH-1, GnRH-2, and GnRH-3 peptides (Table 1.1) in human breast, colon, pancreas, and 
prostate cancer cells to that in the non-tumor cell line such as Madin-Darby canine kidney 
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epithelial (MDCK) cells. This study also revealed that human pharynx tumor cells similarly 
overexpress GnRH receptors on cell surfaces such as human breast, colon and prostate cancer cell 
lines. In contrast, pancreatic tumor cells (BxPC-3) do not present GnRH-1 receptors on their 
membranes.28 As expected, GnRH peptides are internalized by tumor cells via active transport 
mechanisms. Although different cancer cell lines vary in their uptake properties for three different 
GnRH peptides, uptake by all tumor cells was significantly higher than in the control MDCK cell-
line, thus indicating the role of GnRH receptor upregulation in tumor cells. 
1.2.5 pH Low Insertion Peptide (pHLIP) 
A pH low insertion peptide (pHLIP; Table 1.1) was developed as a pH-dependent cell-
penetrating peptide for drug delivery33. pHLIP is a water-soluble membrane peptide that interacts 
weakly with cell membranes at neutral pH; however, when the cell surface is slightly acidic, the 
pHLIP peptide is inserted into the cell membranes as a stable transmembrane -helix. Its primary 
sequence is characterized by acidic residues (i.e., Asp or Glu) that can be protonated at the low 
extracellular pH observed in tumors. In testing the concept, six pHLIP derivatives were conjugated 
to monomethyl auristatin F (MMAF) to make pHLIP-MMAF conjugates and the MMAF is 
attached to the pHLIP C-terminus via a S-S bond that can be cleaved in the cytoplasm.33 The 
efficacy of six pHLIP-MMAF conjugates was evaluated in vitro against cultured cancer cells to 
find the lead conjugate. In vivo, the lead conjugate showed significant therapeutic efficacy in 
mouse models without overt toxicities. pHLIP-MMAF was localized in cancer cells and inhibited 
the proliferation of cancer cells in a pH-selective and concentration-dependent manner. 
1.2.6 MMP Peptides 
Tumor cells have a high expression of MMPs (MMP-2 and MMP-9) that are important in 
tumor proliferation and metastasis.34 One MMP-hexapeptide, PVGLIG, has a high binding affinity 
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to matrix metalloprotease-2 (MMP-2) enzyme. Conjugated to PTX at the C-terminus of the MMP 
peptide via an ester bond, PTX-MMP was found to deliver PTX in a tumor-specific manner.35 
Incubation of PTX-MMP with MMP2, as well as with cancer cells (i.e., HT-1080 and U87MG), 
releases PTX from the conjugate. PTX release was higher in HT-1080 and U87MG cells compared 
to negative control cells (i.e., Hep-2 and Hep G2), suggesting the involvement of MMPs in both 
cancer cells.35 PTX-MMP shows significantly higher cytotoxicity in HT-1080 and U87MG cells 
compared to PTX alone, with no difference in toxicity between PTX-MMP and PTX on Hep-2 
and Hep G2 cells, which have low expression of MMPs. Mice implanted with HT-1080 or U87MG 
cells have a higher survival rate when treated with PTX-MMP compared to those treated with PBS, 
PTX, and the MMP hexapeptide.35 These results support a role for the peptide and MMP-2 in the 
activity of the PTX-MMP conjugate against tumor cells. 
1.2.7 A Combination of Peptides 
A combination of two peptides has been used to target drugs to certain cells. Angiopep (ANG) 
peptide has been used alone or in combination with other peptides (i.e., TAT peptide) to deliver 
drugs to neuronal cells. ANG peptide (Table 1.1) was derived from the ligand of a low-density 
lipoprotein-related protein 1 (LRP1) receptor that is involved in the uptake and processing of 
amyloid precursor protein (APP) in the intracellular compartment inside endosomal vesicles.36 
LRP-1 has been shown to mediate transport of various ligands across the BBB.37 To prove the 
concept, ANG peptide alone was conjugated to -secretase inhibitor (SI) (i.e., ANG-SI and ANG-
PEG-SI; Table 1.1) for endosomal delivery of neuronal cells to inhibit the formation of amyloid-
beta (A).36, 38 Neuroblastoma cells internalize ANG-SI conjugate better than SI peptide alone, 
suggesting that the uptake is through receptor-mediated endocytosis. Conjugation of ANG to SI 
peptide alters the recognition of the ANG peptide by LRP1 receptors because the uptake of ANG-
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SI is unaffected in the absence of LRP1. This suggests the involvement of another receptor in the 
uptake of the conjugate.36 
A combination of ANG and TAT peptides was used to deliver PTX as a conjugate (ANG-
TAT-PTX) across the BBB, and this conjugate was developed to treat glioblastoma brain tumor.37  
ANG-TAT-PTX is expected to bind and be internalized by the LRP-1 receptor across the BBB.  
In previous studies, a conjugate of PTX with angiopep-2 and -3 (ANG1005) has been shown to 
cross the BBB and was investigated in clinical trials.39, 40 The cellular uptake of ANG-TAT by 
U87 glioblastoma cells was higher than that of ANG alone.37 It is interesting to find that, although 
ANG-TAT and TAT-ANG were both internalized by U87 glioblastoma cells, only ANG-TAT 
crossed the BBB.37 The brain delivery studies were done using Biotin-ANG-TAT and this 
conjugate was detected in brain tumor tissue. Biotin-ANG-TAT has significantly higher deposition 
(1.8 times) than Biotin-ANG; in this case, the TAT peptide improved brain tumor uptake. ANG-
TAT-PTX-treated mice with implanted U87 glioblastoma cells in the brain have better survival 
rate than diseased mice treated with ANG-PTX or PTX alone.37 Therefore, TAT peptide is 
important in improving the conjugate brain delivery. 
A combination of T10 and extracellular signal-regulated kinases (ERK) peptides (Table 1.1) 
was also used to deliver DOX molecule to breast cancer cells to overcome drug resistance.41 T10 
peptide binds to and can be internalized by transferrin receptor (Tfr), which is overexpressed in 
tumor cells. ERK peptide can prevent activation of ERK by inhibiting phosphorylation and its 
binding mitogen-activated protein kinase (MEK). T10 peptide was conjugated to ERK peptide via 
a spacer (GGCG), and the thiol group on the Cys residue was linked to DOX to give T10-ERK-
DOX conjugate. The DOX cellular uptake in MCF7/ADR cancer cells was increased when 
attached to the conjugate. The conjugate reversed the drug resistance by downregulating Pgp 
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expression and inhibiting ERK phosphorylation. Although T10-DOX delivered DOX to 
MCF7/ADR cancer cells and suppressed MCF7/ADR xenograft in nude mice, T10-ERK-DOX 
had better efficacy than T10-DOX in suppressing growth of MCF7/ADR tumor xenografts in nude 
mice.42 This indicates that a combination of two peptides with different mechanisms improves the 
outcome of tumor suppression activity. 
The concept of dual peptide targeting was also applied to PEGA peptide (Table 1.1) that binds 
a membrane-bound proline-specific aminopeptidase P (APaseP). APaseP is expressed 
approximately 100-fold higher in vasculature and malignant lesions in breast cancer than in normal 
tissues.43 Thus, PEGA-TAT-TAMRA conjugate was used to evaluate cellular delivery and 
localization of the peptide in breast cancer cells.43 The conjugate was internalized by cancer cells 
in vitro and in vivo in tumor xenografts. Although conjugation of PEGA to TAT resulted in reduced 
selectivity for PEGA to APaseP, the overall results of uptake and localization of the dual peptide 
conjugate showed selective delivery to breast cancer tissue.43 Thus, this dual peptide has the 
potential to delivery cytotoxic drugs to tumor cells in vivo. 
1.3 Peptide-Particle Conjugates for Drug Delivery 
Nanoparticles are another emerging technology to improve drug delivery to a specific type of 
cells. One potential advantage of nanoparticles is that they can be used to store the drug and deliver 
it in a controlled-release fashion. The drug release can be coupled to the different redox conditions 
between the extra- and intra-cellular environments of the cell because of elevated concentrations 
of reductive substances in tumor cells, which differentiate them from normal cells.44, 45 Certain 
types of nanoparticles are generated due to self-assembly and micelle formation of the components 
in water because of their low critical micelle concentration. The micelles normally have high drug 
encapsulation efficiency. One example is PEGylated chitosan-based glycolipid, which can form a 
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redox-responsive nanocarrier system called A54-PEG-CSO-ss-SA. The nanoparticles were 
studded with A54 peptide (Table 1.1) conjugated to a PEG moiety. The nanoparticles were loaded 
with DOX and directed to human hepatoma cells by A54 peptide.46 The PEG moiety also serves 
to increase the in vivo half-life of nanoparticles by avoiding uptake by the reticuloendothelial 
(RES) system. In vitro and in vivo studies of nanoparticles show that DOX can be released via 
reduction of the disulfide bond depending on the amount of reductive substances in the tumor 
cells.46   
Recently, some efforts have been shifted from targeting drugs to specific types of cells to 
targeting them to subcellular organelles (e.g., the nucleus or mitochondria). In this case, the drug 
delivery systems are decorated with ligands that are specific for subcellular compartments, 
including nuclear localization signal (NLS) and the lipophilic triphenylphosphonium (TPP) cation. 
Both NLS and TPP can penetrate the nucleus because of their high affinity for nuclear pore 
complexes and can anchor to mitochondria via electrostatic interactions.47, 48 Previously, drugs 
conjugated with NLS or TPP failed to reach the nucleus or mitochondria because the design of 
these conjugates was not favorable for entering cancer cells from the extracellular space.49, 50 To 
overcome this problem, a (N-(2-hydroxypropyl) methacrylamide (HPMA) polymeric delivery 
system was conjugated to G3-C12 peptide (Table 1.1), a galectin-3-targeting ligand. The ligand 
was used for cellular uptake by cancer cells as well as subcellular mitochondria inside the cells.51 
An antibiotic KLA peptide (Table 1.1) was also conjugated to HMPA to give a G3-C12-HPMA-
KLA delivery system. The in vitro studies showed increased receptor-mediated internalization into 
PC-3 cells with overexpressing galectin-3. Moreover, the specific binding between galectin-3 and 
the G3-C12 peptide directed HPMA-KLA conjugates to the mitochondria with enhanced 
cytotoxicity. An in vivo study revealed that the G3-C12 peptide significantly enhanced the tumor 
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accumulation of the polymer conjugate, exhibiting the best therapeutic efficacy and an improved 
survival rate in animals.51 
Carboplatin has been used to treat ovarian cancer; however, the uptake of carboplatin by 
ovarian cancer cells becomes poor because of drug resistance upon multiple treatments of cancer 
cells. Thus, the poly(amidoamine)-b-poly(aspartic acid)-b-poly(ethylene glycol) (PAMAM-PAsp-
PEG) system was designed to improve carboplatin delivery to ovarian cancer cells (OVCAR-3). 
The nanoparticles utilize RGD-2 peptide (Table 1.1) to direct them to OVCAR-3 cells that have 
overexpression of cell surface V3 and V5 integrin receptors. Carboplatin molecules were 
attached to the polymer via a coordination complex with two carboxylic acid on the poly-aspartic 
acid tethered to the polymer. The release of carboplatin was pH-dependent, and 88% of carboplatin 
was released from the polymer over 50 h at pH 5.5, while only 18% of carboplatin was released 
over 50 h at pH 7.4. To track the cellular uptake and localization of the polymer in OVCAR-3 
cells, Cy5-dye was also connected to the particles via PEG linker.52 The results showed that the 
particles containing RGD-2 peptide were efficiently internalized by the cells compared to particles 
without RGD-2 peptide. The targeted particles have significantly higher toxicity to the cells than 
carboplatin alone. It was proposed that carboplatin was occurring in the lysosome due to pH change 
and protonation of the carboxylic acid of the Asp residues.52 
A new drug self-delivery system (DSDS) was designed as nanocarrier for delivering PTX; in 
this case, PTX was conjugated to octadecanol via a disulfide bond to produce PTX-ODN. The 
PTX-ODN can self-assemble to form nanoparticles, and Pep-1 (Table 1.1) recognized by 
overexpressed interleukin-13 receptor α2 (IL-13Rα2) was used to direct the particles to 
glioblastoma multiforme (GBM) and for crossing the BBB and blood-brain-tumor barrier.53 In this 
case, the Pep-1-PEG-DSPE conjugate is used to incorporate Pep-1 on the DSDS. The PTX-loaded 
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nanoparticles were engulfed by IL-13Rα2 receptor-mediated endocytosis into glioblastoma cells 
and disintegrated in the endosomes to release PTX-ODN component.53 The disulfide bond of PTX-
ODN was reduced in the endosomes by glutathione to release PTX.53 To follow the uptake and 
movement of the nanoparticles inside U87MG cells, the particles were labeled with coumarin-6 
fluorophore. It was confirmed that the nanoparticles were internalized by U87MG cells in a 
receptor-mediated manner. In vivo, the nanoparticles can be detected in the U87MG glioma brain 
tumor grafted in nude mice.53 Brain tumor mice treated with Pep-1-PTX-nanoparticles showed a 
higher survival population than those treated with vehicle, taxol, and PTX-octadecanol 
conjugate.53 
Nanosize particles (PEG-EGFR-PTX) were constructed using branched PEG conjugated to 
PTX and an epidermal growth factor receptor (EGRF) peptide (Table 1.1). The nanoparticles were 
designed to improve PTX delivery to cancer cells with overexpressing EGFR.18 The role of PEG 
was to increase drug water solubility and half-life of the particles. The abilities of PEG-EGFR-
PTX, PTX-PEG, and PTX to inhibit cell growth were evaluated in squamous cell carcinoma of the 
head and neck (SCCHN) cell line. The results showed that the IC50s of PEG-EGFR-PTX, PTX-
PEG, and PTX were 21.74, 8.05, and 1.47 nM, respectively.18 The lower activity of PEG-EGFR-
PTX compared to PTX alone may be due to the less efficient uptake of the PEG-EGFR-PTX 
particles rather than to passive diffusion of PTX. Unfortunately, the toxicities of PEG-EGFR-PTX 
particles and PTX were not compared between EGFR overexpressing cancer cells and normal cells 
to prove particle targeting by EGFR peptide. Therefore, it is difficult to evaluate the usefulness of 
the particles in treating tumors in vivo. 
A conjugate of peptide in nanobubbles (NBs) was designed to deliver small interfering RNA 
(siRNA) molecules, which have high specificity for the oncogenic mRNA in cancer cells. siRNA 
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molecules are known to have unfavorable physicochemical properties (size and anionic charges) 
for partitioning and crossing the cellular membranes to enter the intracellular space and exert their 
activity. To overcome this problem, Myc siRNA was conjugated to CPP (Table 1.1) to give CPP-
Myc siRNA, which is encapsulated in ultrasound sensitive NBs. Ephrin peptide (YSA peptide, 
Table 1.1) was attached to the surface of NBs using 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy-(polyethylene glycol) (DSPE-PEG) to give CPP-siRNA/YSA-
NB.54 YSA peptide selectively binds to overexpressed EphA 2 protein on the cell surface.54 After 
cellular uptake, the CPP-Myc siRNA was released from NBs upon exposure to ultrasound that 
induced apoptosis of MCF-7 breast cancer cells in vitro. CPP-Myc siRNA/YSA-NB with 
ultrasound significantly suppressed tumor growth of MCF-7 xenografts in mice compared to 
without ultrasound.54 The CPP-Myc siRNA/YSA-NB+ultrasound was significantly more effective 
than controls CPP-NC-siRNA/YSA-NB+ultrasound or CPP-siRNA alone, suggesting that YSA 
and ultrasound improved the efficacy of the CPP-Myc siRNA. 
To reduce premature drug release, prodrug nanomedicine was developed to increase stability 
and solubility and to reduce injection of inactive carriers.17 Clinical trials of prodrug carriers such 
as albumin-PTX have shown promise. When formulating prodrug nanomedicine, PEGylation of 
the drug is often used as carrier because PEGylation is non-toxic and non-immunogenic and can 
improve the half-life of the drug in circulation.17 A cleavable linker between the drug and the 
carrier is also an essential component. The cis-asconitic anhydride-DOX (CAD) was conjugated 
to a PEG group via an amide bond to make a PEG-CAD prodrug. Then, the PEG-CAD prodrug 
was conjugated to RGD-3 peptide (Table 1.1), which selectively binds to neuropilin-1 (NRP-1) 
receptors. NRP-1 receptors have been shown to be overexpressed in tumor vessels as well as in 
many human cancer cell lines. The conjugation utilized a thiol-ene reaction to give an acid-labile 
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prodrug called PEG-CAD-RGD-3. Due to the amphiphilic nature of PEG-CAD-RGD-3, it 
assembled into nanoparticles in water. During in vitro and in vivo administration, the release of 
DOX was triggered in acidic pH, but was restricted in neutral pH environment. Compared to DOX 
alone, the presence of RGD-3 peptide improved nanomedicine endocytosis and cytotoxicity into 
tumor cells. In Balb/c mice, PEG-CAD-RGD-3 nanomedicine has shown prolonged accumulation 
of DOX in tumors.17 
1.4 Peptide Modulation of Biological Barriers to Improve Drug Delivery 
1.4.1 The Blood Brain Barrier (BBB) and the Intestinal Mucosa Barrier (IMB)  
Biological barriers such as the intestinal mucosa barrier (IMB) and blood-brain barrier (BBB) 
are present to protect the body from infections entering into the systemic circulation and the central 
nervous systems (CNS), respectively.55 IMB is composed of a single layer of epithelial cells at the 
luminal side of the gastrointestinal tract followed by the lamina propria and the muscularis 
mucosae. The BBB is comprised of the luminal and abluminal membranes of the brain capillary 
endothelium as the major route for molecules (drugs and diagnostic agents) to enter the brain.56 
The IMB and BBB function as selective filters to allow needed substances and nutrients to enter 
the systemic circulation or brain, respectively, while preventing unwanted substances such as 
toxins from crossing the barriers. The gastrointestinal tract, skin, kidney, and lung barriers are 
made up of epithelial cells while the BBB microvessels are composed of endothelial cells. The 
delivery of molecules through the IMB and BBB is normally via the transcellular and paracellular 
pathways. Passive diffusion of drugs through the transcellular pathway depends on 
physicochemical properties of the drugs, and the passive diffusion of these drugs is normally 
regulated by Lipinski’s rules of five. In general, peptide and protein drugs cannot cross the 
transcellular pathways due to their size, hydrophilicity, and hydrogen bonding potential. However, 
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some hydrophilic small and large molecules (e.g., peptides and proteins) can cross the biological 
barriers via the transcellular pathway using receptor-mediated transporters. 
Alternatively, drug molecules could cross the IMB and BBB via the paracellular pathway, 
where molecules pass through the intercellular space between the cells.57, 58 The paracellular space 
or intercellular junctions are connected by cell-cell adhesion proteins, forming a contiguous 
membrane connection.59, 60 Therefore, there is a size limit for molecules to cross the paracellular 
pathway; normally, only ions and molecules with hydrodynamic radius <11 Å can cross this 
pathway.61 This limitation is imposed by the tight junctions that are mediated by cell-cell adhesion 
proteins such as occludins, claudins, and junction adhesion molecules (JAMs), which act as a fence 
to prevent free diffusion of molecules (Figure 1.1). Below the tight junctions there are adherens 
junctions (AJ), which are mediated by nectin and calcium-binding cadherins.62 Beneath the 
adherens junctions lie the desmosomes, which are composed of desmoglein and desmocollin 
proteins; these proteins are also part of the cadherin family of cell-cell adhesion molecules with 
calcium-dependent binding properties.63 
Modulation of the intercellular junctions of the IMB and BBB have shown promise in 
enhancing paracellular permeation of molecules. A hypertonic mannitol solution is used clinically 
to deliver anticancer drugs to treat terminally ill brain tumor patients.64-66 This method is called 
osmotic delivery because the hypertonic solution shrinks the BBB vascular endothelial cells and 
modulates the intercellular junctions to increase their porosity. Various chemicals as specific and 
nonspecific junction modulators (i.e., sodium caprate, sodium decanoate, oleic acid, 
ethyleneglycol-bis-(β-aminoethyl ether)-N, N′-tetraacetic acid (EGTA)) have successfully 
improved penetration of molecules through in vitro models of biological barrier.61 Due to 
uncontrolled paracellular opening, many toxic and unwanted side effects were observed with some 
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of these methods. Thus, much research is focused on designing synthetic peptides that selectively 
modulate the protein-protein interactions in the intercellular junctions to improve paracellular 
permeation of delivered molecules. 
1.4.2 Peptide Modulation of Tight Junction Proteins 
One way to improve delivery of drug molecules via paracellular pathways of IMB and BBB is 
by modulating the interactions of cell-cell adhesion proteins in the intercellular junctions to 
increase the porosity of the paracellular pathways.58, 67 Several peptides derived from occludins 
have been synthesized and evaluated for this purpose. Occludins are 60 kDa membrane proteins 
that are involved in maintaining tight junction integrity. They are composed of four transmembrane 
domains, three cytoplasmic domains, and two extracellular loops of approximately similar size. 
One of these extracellular loops contains more Tyr and Gly residues.68 The OCC2 peptide derived 
from extracellular loop 2 has been shown to modulate the tight junctions of A6 cell monolayers; 
the peptide lowers the transepithelial electrical resistance (TEER) values of the monolayers.69 
OCC2 also enhances the penetration of paracellular markers such as inulin, dextran 3000, and 
dextran 40,000 across the A6 cell monolayers, indicating that the peptide increases paracellular 
porosity. OP90-135 peptide (Table 1.1) derived from the first loop of occludin can lower the TEER 
values of Caco-2 cell monolayers, a model for IMB.70 The peptide also enhanced the transport of 
a paracellular marker, 14C-mannitol, across the Caco-2 cell. A smaller OP90-103 peptide (Table 1.1) 
has better modulatory activity than the parent OP90-135 in Caco-2 cell monolayers. In addition, Lip-
OP90-103 peptide (Table 1.1) that is an N-terminus lipid-alkylated peptide has about 11 times higher 
modulatory activity than the parent OP90-103.  
Besides the occludins, claudins (Cldn-1, -2, -3, and -4) are also responsible for forming tight 
junctions; claudins have a transmembrane structure similar to that of occludins.59, 60, 68 They have 
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a short cytoplasmic N-terminus, two extracellular loops, and a C-terminal cytoplasmic domain. 
Both occludins and claudins interact via their C-terminus to zonula occludin-1 (ZO-1), ZO-2, and 
ZO-3 and stabilize the cytoskeleton membranes of the tight junctions. Knocking down the 
expression of Cldn-1, Cldn-4, occludin, and ZO-1 increases the paracellular permeation of 
molecules and ions across the cell monolayers.60 This result confirms their importance in 
maintaining the tight junctions. A 29-amino acid C1C2 peptide derived from the extracellular loop-
1 of claudin-1 can enhance the permeation of small and large paracellular markers (i.e., Lucifer 
Yellow and FITC-Dextran 10 KDa) across the cell monolayers.71 In vivo, the peptide increases the 
brain delivery of tetrodoxin and enkephalin peptides, suggesting that the peptide modulates the 
tight junctions of the BBB. The proposed mechanism of action of C1C2 peptide is via binding to 
claudins followed by induction of claudin endocytosis into the cytoplasmic domain.72 Therefore, 
this internalization lowers the population of claudin in the tight junction to make the tight junctions 
looser.  
1.4.3 Peptide Modulators of Adherens Junction Proteins 
Peptides derived from the extracellular domain-1 (EC1) domain of E-cadherin (i.e., HAV and 
ADT peptides) have been shown to modulate the intercellular junctions of MDCK and Caco-2 cell 
monolayers.73, 74 It is proposed that these ADT and HAV peptides modulates the adherens junction 
in the intracellular junction to make the BBB porous by inhibiting the binding of E-cadherin 
mediated cell-cell adhesion (Figure 1.2) and it has been shown in vivo and in vitro experiments 
including bovine brain microvessel endothelial cells (BBMEC).61, 75 HAV6 and/or ADTC5 
peptides (Table 1.1) increase the in vivo brain delivery of molecules in mice and/or rats; the 
delivered molecules include paracellular markers (i.e., 14C-mannitol, 25 kDa IRdye800cw-
polyethylene glycols or PEG), anticancer drugs (i.e., 3H daunomycin, Glu-CPT), efflux pump 
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substrates (i.e., rhodamine 800 (R800), 3H daunomycin), magnetic resonance imaging (MRI) 
enhancing agents (i.e., gadopentetic acid or Gd-DTPA), peptides (i.e., IRdye800cw-cLABL and 
cIBR) and proteins (i.e., 65 kDa galbumin).76-79 The brain depositions of radioactive molecules 
such as 14C-mannitol and 3H-daunomycin were detected and quantified in the brain homogenates 
using a radioactive counter, while the quantity of brain deposition of R800, IRdye800cw-PEG, 
and IRdye800cw-cLABL was determined in the intact isolated brain using near IR fluorescence 
imaging. MRI was used in living animals to detect the brain distribution of Gd-DTPA and 
galbumin. Finally, the amounts of brain delivered non-labeled Glu-CPT and cIBR peptide in rats 
were detected using LC-MS/MS. The duration of modulation of the in vivo BBB for small 
molecules was less than 1 h for HAV6 peptide and between 2 and 5 h for ADTC5 peptide.77, 80 
However, the duration of BBB modulation by HAV6 and ADTC5 was short for delivering a large 
molecule such as 65 kDa galbumin, less than 10 min for HAV6 and from 10–40 min for ADTC4 
peptide.78 The results suggest that the peptides create small pores in the intercellular junctions with 
a long-time duration compared to a short duration for large pores in the BBB intercellular 
junctions. The results also indicate that the BBB modulation is reversible. 
 The mechanism of action of HAV and ADT peptides is hypothesized via their binding to E-
cadherin to inhibit cadherin-cadherin interactions in the intercellular junctions of the BBB (Figure 
1.2). Using nuclear magnetic resonance spectroscopy (NMR) and molecular docking studies, the 
HAV and ADT peptides were shown to bind at different sites on the EC1 domain of E-cadherin.81 
It is proposed that the HAV6 peptide binds to the EC1 domain and inhibits the binding of the EC1 
domain from one E-cadherin to the EC2 domain of another cadherin from the same membranes, 
which is the cis-cadherin interaction. In contrast, ADTC5 peptide binds to the EC1 domain to 
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prevent the trans-EC1 domain from swapping between two E-cadherins from opposite cell 
membranes or trans-cadherin interactions.  
1.4.4 Other Peptide Modulators of Tight Junctions 
Bocsik et al. have shown that C-CPE, AT-1002, PN-78, and PN-159 peptides (Table 1.1) could 
modulate the intercellular junctions of the IMB and BBB in cell culture models.67 These peptides 
were not derived from the sequence of proteins form the intercellular junctions of the IMB and/or 
the BBB.  C-CPE and AT-1002 peptides were respectively derived from clostridium perfringens 
enterotoxin (C-CPE) and zonula occludens toxin (Zot). Both peptides modulate the penetration of 
molecules through the paracellular pathways of IMB and BBB in vitro and/or in vitro.67, 82 AT-
1002 peptide enhances the oral absorption of low molecular weight heparin and calcitonin in 
vivo.83 PN-78 and PN-159 peptides were discovered using phage display and they increased the 
paracellular permeation of molecules through the lung epithelial cell monolayer.84 C-CPE, AT-
1002, PN-78, and PN-159 modulate the intercellular junctions of Caco-2 cell and brain endothelial 
monolayers as models of IMB and BBB, respectively. This junction modulation was reflected in 
the lowering of trans-epithelial/endothelial electrical resistance (TEER) upon peptide treatment. 
The paracellular transport of fluorescein across the Caco-2 cell monolayers was enhance by C-
CPE, AT-1002, PN-159 but not PN-78 peptides. However, all four peptides enhanced the 
penetration of albumin across the Caco-2 cell monolayers. The paracellular permeation of both 
fluorescein and albumin across the BBB cell monolayers was increased by AT-1002, PN-78, and 
PN-159 but not C-CPE. Thus, these peptides can be used to deliver drug molecules across the IMB 




Peptides have been successfully developed as drugs. Now, peptides have been extensively 
investigated to deliver drugs to specific cells to lower the side effects of the drugs. Similarly, 
conjugation of peptides to labeled molecules or atoms was shown to be useful for potential 
diagnostic agents to locate diseased cells within the body using various detection methods such as 
MRI and PET. Finally, delivery across the intestinal mucosa and the blood-brain barrier can also 
be enhanced by modulation of the protein-protein interactions in the intercellular junctions of these 
barriers using peptides. Modulation of the BBB using cadherin peptides can enhance the brain 
delivery of small-to-large molecules to the brains of living animals. Thus, modulation of the 
intercellular junctions can be exploited to deliver drug and diagnostic molecules through the IMB 
and BBB in the clinic in the future. 
1.6. Thesis and Chapter Goals 
1.6.1. Overall Goals of the Thesis 
The overall goals of the thesis were to (a) deliver peptides and proteins to the brain by 
modulating the BBB using cadherin peptides, (b) develop analytical methods to quantify protein 
brain depositions, and (c) to design new cyclic peptides for improving BBB modulatory activities 
that are more successful than the current existing modulating peptides. 
1.6.2. Chapter 2 
The goal of this project was to show that cadherin peptides (ADT and HAV) can enhance the 
brain delivery of a large protein, 65 kDa galbumin, and different sized peptides (i.e., cIBR7, 
cLABL). The study showed that ADTC5 and HAV6 can enhance the brain delivery of galbumin, 
cIBR7, and cLABL peptides as detected by magnetic resonance imaging (MRI), mass 
spectrometry, and NIRF imaging methods, respectively. The results also indicated that the 
durations of the BBB opening for large molecules created by ADTC5 and HAV6 peptides were 
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short compared to that created by a small marker (e.g., R800 and Gd-DTPA). In addition, a LC-
MS/MS method was developed and validated for the detection of a brain-delivered peptide, cIBR7, 
which could efficiently detect and quantify the amounts of peptide in the brain.  Overall, this study 
found that ADTC5 and HAV6 can increase the brain delivery of different molecules by modulating 
the BBB in mouse and rat models. Finally, it was concluded that BBB modulation by cadherin 
peptides depends on (a) the type and dose of the modulator peptide, (b) the timing of delivery 
between the BBB modulator and the delivered molecule, and (c) the size of the delivered 
molecules.  
1.6.3. Chapter 3 
The goal of this project was to evaluate the modulatory activities of HAV6 and ADTC5 for 
brain delivery of different sizes of proteins such as 15 kDa lysozyme, 65 kDa albumin, 150 kDa 
IgG mAb, and 220 kDa fibronectin. A novel NIRF method was developed and validated to 
quantitatively determine the brain deposition of IRdye800CW-conjugated proteins (i.e., lysozyme, 
albumin, IgG mAb, and fibronectin). ADTC5 showed an improved delivery of lysozyme, albumin, 
and IgG mAb into the brains of C57BL/6 mice while HAV6 enhanced only the brain delivery of 
lysozyme. It was found that the cut-off limit for HAV6 peptide is 65 kDa, while ADTC5 can 
deliver molecules with the size of mAb, or less than 220 kDa. Furthermore, ADTC5 and HAV6 
peptides could enhance depositions of delivered proteins in different organs (e.g., kidney and/or 
liver).  
1.6.4. Chapter 4  
The goal of this project was to design and synthesize novel cyclic peptides derived from 
ADTC5 and HAV6 sequences or a combination of them to improve their biological activity and 
plasma stability for use as BBB modulators. Linear and cyclic ADTHAV peptides were designed 
41 
 
and synthesized from the sequences of ADTC5 and HAV6 peptides using a N-to-C-terminal 
cyclization method.  Cyclic HAVN1 and HAVN2 peptides were derived from the sequence of 
linear HAV6 peptide to achieve more stability and potency. The cyclic HAVN1 and HAVN2 
peptides showed better activity than linear HAV6 peptide for enhancing IRdye-800CW Donkey 
anti-Goat IgG mAb brain delivery in C57BL/6 mice. Cyclic ADTHAV peptide has a better binding 
affinity to the EC1 domain of cadherin than ADTC5 peptide, as determined by surface plasmon 
resonance (SPR). Linear and cyclic ADTHAV peptides as well as ADTC5 peptide significantly 
enhanced the delivery of IgG mAb compared to control in C57BL/6 mice. It seemed that cyclic 
ADTHAV improved brain delivery of IgG mAb more than did linear ADTHAV (p = 0.07).  
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Figure 1.1  Schematic of cell adhesion proteins at intracellular junction in the blood-brain barrier (BBB). 
It consist of tight junction (TJ), adherens junction, and desmosomes. The TJ are mediated by occludins, 
claudins, junctional adhesion molecules (JAM), and zonula occludins-1, -2 and -3. Adherens junctions 
that are below the tight junctions are mediated by cadherins and nectins. Desmosomes are mediated by 




Figure 1.2  Schematic of the proposed modulation for the intracellular junction in the blood-brain barrier 
(BBB). (A) In normal condition, the E-cadherins are tightly attached together preventing the passage of 
drugs from the blood side to the brain side. (B) Once the peptide is in blood, these ADT or/and HAV 
peptides inhibit the cell-cell adhesion in an equilibrium and dynamic fashion to allow the drug to pass 
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There is an urgent need to develop new and alternative methods to deliver molecules to the 
brain for diagnosis and treatment of brain diseases (i.e., Parkinson’s, Alzheimer’s, multiple 
sclerosis, brain tumors).1, 2 Furthermore, approaches that can safely deliver molecules to the brain 
can also provide opportunities to probe brain functions at the cellular and molecular levels using 
selected imaging and cellular signaling molecules. The protective function of the BBB selectively 
restricts molecules from entering the brain; however, under pathological conditions, the BBB can 
also restrict the accumulation of drugs to the brain. Numerous invasive methods have been 
developed to directly deliver or sample molecules to or from the brain, respectively; these methods 
include (a) brain microdialysis,3, (b) intracerebral implantation,4 and (c) intraventricular delivery.5 
However, these methods can be problematic for patients, and these invasive approaches can cause 
damage in the surrounding brain tissues. Alternatively, various non-invasive approaches have been 
developed to improve brain delivery of molecules, including the use of (a) prodrug technology, (b) 
efflux pump inhibitors, (c) receptor-mediated transport, (d) osmotic agents, and (e) BBB 
modulators; however, in general, the success of these methods has been limited.1, 2, 6, 7 
One way to deliver drug and diagnostic molecules to the brain is via the transcellular pathway, 
allowing the molecule to diffuse through the membranes of the BBB endothelial cells. 
Traditionally, changing the physicochemical properties of the drug was done to improve its brain 
delivery via the transcellular pathway. However, changing the drug structure may alter its 
biological activity. As an alternative, several prodrug methods have been developed to transiently 
change the physicochemical properties of the drug, permitting greater transcellular BBB 
penetration.1 Although the physicochemical properties of the drug can be changed to improve its 
membrane partition for transcellular passive diffusion, the presence of efflux pumps on the BBB 
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can prevent the drug molecule from crossing the BBB cell membranes. Inhibitors have been 
designed to block the activity of efflux pumps in allowing the drug to cross the BBB.1 Receptor-
mediated transcytosis has also been explored for improving brain delivery of molecules. For 
example, the high expression of transferrin receptors on the luminal side of brain capillary 
endothelial cells has been exploited as a carrier of drugs/macromolecules across the BBB, and has 
shown promise in pre-clinical animal models.2, 8 
 
Table 2.1.  Peptide Names and Peptide Sequences 
Peptide  Sequence Peptide Origin 
HAV6  Ac-SHAVSS-NH2  EC1 of E-cadherin 
HAV4  Ac-SHAVAS-NH2 Ala5 mutant of HAV6 
cHAVc3  Cyclo(1,6)Ac-CSHAVC-NH2 EC1 of E-cadherin 
ADTC5 Cyclo(1,7)Ac-CDTPPVC-NH2 EC1 of E-cadherin 
cLABL Cyclo(1,12)PenITDGEATDSGC I-domain of LFA-1 
cIBR7 Cyclo(1,8)CPRGGSVC D1 of ICAM-1 
IS Cyclo(1,8)CPRGGSIC Ile7 mutant of cIBR7 
 
An alternative approach to deliver molecules across the BBB is via the paracellular pathway 
by increasing the porosity of the intercellular junctions. Under normal conditions, the penetration 
of molecules through this pathway is limited by the presence of the tight intercellular junctions. 
Therefore, modulation of these junctions is needed to improve paracellular passive diffusion of 
molecules. One successful method for enhancing paracellular delivery across the BBB that has 
been used in the clinic to deliver anticancer drugs to brain tumor patients is hyperosmotic agents 
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such as mannitol. In this case, administration of osmotic agents is used to produce a hypertonic 
environment within the brain vasculature, causing shrinkage of endothelial cells of the BBB and 
allowing opening of the tight junctions for molecules to cross via paracellular pathways.9 The 
positive results from the osmotic method have stimulated investigation of other methods to 
transiently modulate the integrity of the BBB to enhance molecule delivery via the paracellular 
pathway. Several molecules have been developed to modulate the intercellular junctions of the 
BBB, including bradykinin derivatives and inhibitors of cell-cell adhesion proteins (i.e., occludins, 
claudins, cadherins).10-13  
Our group have designed and utilized cadherin peptides called HAV (His-Ala-Val)14 and ADT 
(Ala-Asp-Thr)15 peptides derived from the extracellular domain-1 (EC1) of E-cadherin (Table 
2.1.) to modulate the intercellular junctions of the BBB and improve paracellular penetration of 
functional biomolecules (i.e., peptides and proteins). Previously, HAV and ADT peptides have 
been shown to enhance the in vivo brain delivery of small-to-large marker molecules (e.g., 14C-
mannitol, gadopentetic acid, and 25 kDa polyethylene glycols (PEG)) in mice and rats.16-20 
However, the utility of HAV and ADT peptides in enhancing in vivo brain delivery of proteins and 
peptides has not yet been evaluated. Thus, the aim of this work was to evaluate the ability of 
cadherin peptides to enhance brain delivery of galbumin, IRdye800cw-cLABL peptide, and 
unlabeled cIBR7 peptide.  
In this study, four different cadherin peptides (HAV4, HAV6, cHAVc3, ADTC5) were 
evaluated in their effectiveness for delivering a large protein, galbumin, a gadolinium-labeled 
albumin magnetic resonance imaging contrast agent, into the brains of Balb/c mice. Both the extent 
and duration of BBB modulation by HAV6 or ADTC5 peptides was evaluated. Galbumin is a 
gadolinium-labeled albumin that can be detected using magnetic resonance imaging (MRI) due to 
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the increase in T1 relaxation rate (1/T1) to produce a positive image contrast in the brain.
21 Due to 
its physicochemical properties (i.e., size, hydrogen binding potential, and hydrophilicity), 
galbumin cannot cross the BBB via the transcellular or paracellular pathways. Therefore, it is a 
good model molecule to test the activity of cadherin peptides to enhance brain delivery of protein 
via the paracellular pathway due to the increase in BBB paracellular porosity.  
Secondly, the brain delivery of IRdye800cw-cLABL peptide was accomplished using ADTC5 
peptide in Balb/c mice. cLABL peptide was derived from the I-domain sequence of lymphocyte 
function-associated antigen-1 (LFA-1) receptors found on the surface of T cells.  The cLABL 
peptide binds to and is internalized by intercellular adhesion molecule-1 (ICAM-1) on the surface 
of vascular endothelial and immune cells.22, 23 Because ICAM-1 is upregulated during 
inflammation, the hypothesis is that labeled cLABL peptide can be used to detect changes in 
ICAM-1 expression in the brain during neuroinflammation. In this study, the brain deposition of 
cLABL was quantified using near-infrared fluorescence (NIRF) imaging. Although this peptide is 
smaller than galbumin, it has unfavorable physiochemical properties for crossing the BBB via the 
transcellular and paracellular pathways, thus, it is also a good model of peptide delivery to the 
brain. 
Finally, this study was carried out to evaluate the brain delivery of unlabeled cIBR7 peptide 
using ADTC5 peptide in Sprague-Dawley rats. The aim is to develop a method to extract and 
detect the unlabeled cIBR7 peptide in the brain to confirm our findings using labeled molecules. 
Sprague-Dawley rats were used to evaluate the applicability of ADTC5 peptide to enhance 
delivery of molecules into rat brains in vivo because ADTC5 has not been used in rat model 
previously. cIBR7 peptide was derived from ICAM-1 sequence and it binds to the I-domain of 
LFA-1 receptor on immune cells (i.e., T cells); therefore, brain delivery of cIBR7 peptide can 
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detect the presence of immune cells in the brain during the neuroinflammation process.24-26 Most 
of our studies to deliver molecules to the brain have been carried out using labeled molecules, and 
their brain deposition was detected using radioactivity, NIRF imaging, and magnetic resonance 
imaging (MRI). One possible caveat of using labeled molecules is that the labeled molecule may 
degrade during delivery. Thus, the detected quantity of the molecule may be due to a combination 
of the intact molecule and its degraded fragments containing the label. Therefore, unlabeled cIBR7 
peptide was delivered using ADTC5 peptide, and brain depositions of cIBR7 and ADTC5 peptides 
were quantified using tandem mass spectrometry (LC-MS/MS).  
2.2 Materials and Methods 
2.2.1 Chemicals, Reagents, and Animals 
Ketamine hydrochloride and xylazine were purchased from MWI Veterinary Supply Co. 
(Boise, ID) and Lloyd Inc. (Shenandoah, IA), respectively. IRdye800cw-NHS ester was purchased 
from LiCOR Inc. (Lincoln, NE). Amino acids for peptide synthesis were purchased from Protein 
Technologies Inc. (Tucson, AZ). Galbumin was purchased from BioPal Inc. (Worcester, MA). All 
other reagents and chemicals were purchased from Sigma Aldrich Chemical Company (St. Louis, 
MO). All protocols involving the use of animals were approved by the Institutional Animal Care 
and Use Committee (IACUC) at The University of Kansas or the University of Manitoba. The 
animals were maintained in the Animal Care Unit with free access to food and water. 
2.2.2 Peptide Synthesis and Purification 
The synthesis of peptides (Table 2.1) was accomplished using a solid-phase peptide 
synthesizer. After peptide cleavage from the resin using TFA, the crude peptides were precipitated 
in cold diethyl ether. In most cases, the crude precipitate showed high concentration of the desired 
peptide. After purification with semi-preparative HPLC, the isolated peptides had high purity 
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(>96%) as determined by analytical HPLC with a C18 column. The formation of a disulfide bond 
in the cyclic peptide (i.e., cIBR7, ADTC5, cHAVc3, IS) was accomplished by stirring the 
precursor linear peptide in bicarbonate buffer solution under air oxidation at pH 9.0 in high 
dilution. The cyclization reaction produced primarily the desired monomer with minor oligomer 
side-products; the monomer was isolated from the mixture using semi-preparative HPLC. Because 
cIBR7, IS, and ADTC5 peptides were quantified in the brain by mass spectrometry, their exact 
mass data are presented in Table 2.2. 








ADTC5 772.293 772.298 6.5 
cIBR7 775.315 775.316 1.3 
IS 789.331 789.336 6.3 
 
To synthesize IRdye800cw-cLABL, cLABL peptide (0.86 mg, 0.71 mol, MW = 1197.2 
g/mol) and IRdye800cw-NHS ester (5.0 mg, 4.2 mol, MW = 1166.2 g/mol with 3 Na+) were 
mixed in 1.0 mL of 0.5 M potassium phosphate buffer at pH 8.5 followed by stirring overnight in 
the dark. The reaction progress was monitored by analytical HPLC with a C18 column. After the 
reaction was completed, IRdye800cw-cLABL (MW = 2248.4 with 3 Na+ and 2182.4 without Na+ 
ions) was purified using HPLC with a C18 semi-preparative column. The identity of the pure 
product was determined using mass spectrometry to give 2182.69 amu for IRdye800cw-cLABL 





2.2.3 In Vivo Delivery of Galbumin in Balb/c Mice and Quantification using MRI 
The effects of cadherin peptides (i.e., HAV4, HAV6, ADTC5, cHAVc3) to enhance brain 
delivery of 65 kDa galbumin were determined in Balb/c mice. A Bruker Biospect MR spectrometer 
equipped with 7 tesla/21 cm magnets and 2.5 × 2.5 cm2 field of view was used to quantify brain 
depositions of galbumin. After anesthesia, Balb/c mice were placed in the MRI magnet followed 
by simultaneous delivery of galbumin (0.6 μmol/kg) with the peptide (0.010 mmol/kg). The brain 
was scanned with a series of T1- and T2-weighted images before initial delivery of galbumin to 
determine the brain background images and structural coordinates.17 Every 3 minutes, T1-
weighted images of the brain were collected for up to 51 min following the injection of galbumin 
with peptide. The galbumin brain deposition was determined using the intensity of the contrast 
agent from manually outlined regions of interest (ROI) within the coronal brain slices using 
Marevisi 3.5 software (Institute for Biodiagnostics, National Research Council, Ottawa, Ontario, 
Canada). Paravision 3.0 software package was used to quantify the increase in image intensity of 
galbumin in the brain using the following formula for percent change:  
[(Post-Gd-DTPA T1-weighted images – Pre-Gd-DTPA T1-weighted images) ÷ Pre-Gd-DTPA T1-
weighted images] × 100. 
2.2.4 In Vivo Delivery of IRdyeR800cw-cLABL into the Brains of Balb/c Mice and NIRF 
Detection 
The effect of ADTC5 in enhancing BBB penetration of IRdyeR800cw-cLABL in Balb/c mice 
was quantified using NIRF imaging as described previously.17 Briefly, IRdye800cw-cLABL (10 
µg/mouse) along with ADTC5 (0.01 mmol/kg) was delivered into Balb/c mice via tail vein 
injection. After 20 min, the mice were sacrificed, followed by cardiac perfusion with 10% 
formaldehyde solution.17  The brains were removed and 1-mm coronal slices prepared for ex vivo 
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quantitative analysis using an Odyssey NIRF imaging system (Licor, Lincoln, NE). The 
depositions of IRdyeR800cw-cLABL peptide in the brain were quantified by integrating the 
fluorescence intensities at the ROI. The integrated fluorescence intensities were normalized to the 
fluorescence from the blood sample at the same time point. The data were presented as the relative 
fluorescence units/mm3 of tissue divided by relative fluorescence units/μL blood. 
2.2.5 In vivo Delivery of cIBR7 into the Rat Brain and LC-MS/MS Detection 
 
ADTC5 peptide was used to deliver cIBR7 in male Sprague–Dawley rats (300–400 g). Rats 
were anaesthetized with a combination of ketamine (100 mg/kg) and xylazine (5 mg/kg) delivered 
intraperitoneally. A heat lamp was used to maintain the animal’s body temperature during the 
experiment. The jugular vein of the rat was cannulated with a polyethylene catheter (PE 50) 
containing heparinized saline (100 IU/mL) through which cIBR7 (40 mg/kg) and ADTC5 (30 
mg/kg) were administered over 10 min. Then, the rats were sacrificed and a heart-cut was 
performed followed by perfusion of the brain with saline to remove leftover peptide in the 
microvessels of endothelial cells of the BBB. The whole brain tissue was isolated and rinsed with 
saline followed by storage at –80 °C. In the meantime, blood was collected in tubes containing 
anticoagulants and centrifuged at 12000 rpm for 10 min. Plasma was obtained and stored at –80 
°C until further processing. Control studies were done following the same procedure but with the 







2.2.6 Capillary Depletion Method 
Parallel capillary depletion experiments were performed as described by Triguero et al.27 to 
ensure that there is no trapping of the delivered molecules in the microvessel endothelial cells. 
Brain homogenates from rat brains dosed with cIBR7 and ADTC5 were mixed together and 
divided into two sets. One set of homogenates (580 μL) was extracted using the optimized 
extraction procedure (see below). The other set of brain homogenates was extracted after capillary 
depletion was performed to remove cerebral vasculature contaminants. In this method, 580 μL of 
26% dextran solution was added to 580 μL of brain homogenate with IS. The mixture was 
centrifuged at 5,400 g for 15 min, and the supernatant was extracted with 1 mL acetonitrile using 
the optimized extraction procedure described below. 
2.3 LC-MS/MS Method Development and Peptide Extraction and Detection Procedures 
Instrumentation and Chromatographic Conditions for Quantitative LCMS/MS Analysis.   
The LC-MS/MS system consisted of an Acquity UPLC system (Waters Corp., Milford, MA) 
coupled to an electrospray (ESI) ion source and a Quattro Ultima triple quadrupole mass analyzer 
(Micromass Ltd., Manchester, UK). Separation was performed at room temperature on a Luna 
UPLC C18 (2.1 mm × 50 mm, 5 μm particle size, 100 Å; Phenomenex, Inc., Torrance, CA) using 
a binary gradient mobile phase consisting of solvents (A) H2O:formic acid (99.92:0.08) and (B) 
acetonitrile:formic acid (99.92:0.08). The gradient was carried out as follows: 1% B (initial–0.5 
min), 1–7% B (3.5 min), 7–18% B (1 min), 18–50% B (1 min), 50–80% B (1 min), 80% B (2 min), 
80–100% B (1 min) and 100% B (1 min). A 20-μL sample was injected into the mobile phase 
flowing at a rate of 0.350 mL/min. Mass spectrometric analysis was conducted in positive ion 
mode using multiple reaction monitoring (MRM). Nitrogen was used as the desolvation gas and 
argon gas was used for collision-induced dissociation (CID). Cone voltages for the analytes and 
65 
 
collision energies were set at 35–55 V and 35–120 V, respectively. MRM chromatograms were 
quantified using MassLynx v 4.1 software (Micromass) for the integration of relevant peak areas. 
Preparation of Stock, Standard, and IS Solutions.   
ADTC5, cIBR7, and internal standard (IS) were dissolved in nanopure water to prepare (1 
mg/mL) stock solutions, which were stored at –20 °C and later diluted for the required working 
standard solutions. Calibrations of standard brain homogenate samples were prepared as follows. 
The working standard solutions (10 µL) and IS (10 µL, target concentration of 200 ng/mL) were 
spiked into 580 μL of blank brain homogenates from untreated rats. These were recovered using 
the extraction procedure given below to yield a linear range from 50 to 500 ng/mL (50, 100, 175, 
250, 350, 500 ng/ml) for the calibration curves. Quality control (QC) samples were prepared in the 
same way. 
Sample Preparation. 
Extraction of peptides from brain tissue: The whole brain was homogenized with 0.25% acetic 
acid using a PowerGen 700 tissue homogenizer. 590 μL aliquots of rat brain homogenate were 
spiked with 10 μL of IS (target concentration, 200 ng/mL). The homogenate was vortexed for 1 
min followed by addition of 1 mL acetonitrile; the mixture was then vigorously vortexed again for 
1 min followed by centrifugation at 12000 rpm. The supernatant was isolated, transferred to a clean 
tube, and evaporated to dryness using a Savant SpeedVac concentrator. The dry extract was 
reconstituted in 100 μL of water, vortexed for 30 s, and centrifuged for 10 min at 12000 rpm to 
remove residual precipitated proteins.  
Extraction of peptides from plasma: 100 μL of rat plasma was spiked with 10 μL of IS (target 
concentration 200 ng/mL). The mixture was vortexed for 1 min followed by addition of 250 μL of 
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acetonitrile. The mixture was vigorously vortexed again for 1 min, followed by centrifugation at 
12000 rpm. The supernatant was isolated, transferred to a clean tube, and evaporated to dryness 
using a Savant SpeedVac concentrator. The dry extract was reconstituted in 100 μL of water, 
vortexed for 30 s, and centrifuged for 10 min at 12000 rpm to remove residual precipitated proteins. 
Extraction Recovery. 
Recovery and matrix effects of cIBR7 and ADTC5 were tested in the spiked rat brain 
homogenates at three concentrations 50, 250 and 500 ng/mL. Extraction recovery of cIBR7 and 
ADTC5 from brain tissue homogenate was determined by the ratios of peak areas in the post-
extraction spiked samples and in pre-extraction spiked samples.  
Accuracy, Precision, and Stability. 
The intra-day as well as inter-day accuracy and precision were calculated by analyzing 
replicates of spiked brain homogenates at three concentrations 50, 250 and 500 ng/mL. The 
stability of the cIBR7 and ADTC5 peptides in spiked brain homogenates was evaluated under 
different temperature and storage conditions. Three sets of samples were subjected to (a) room 
temperature for 10 h, (b) −20 °C for 24 h followed by unassisted thawing at room temperature, 
and (c) three freeze-thaw cycles between −20 °C and room temperature over a 24-h period. The 
total chromatogram time for one sample was 11 min, and the total duration for a set of samples for 
the experiment per day was less than 8 h. All stability studies were conducted using 50, 250, and 





2.3.1 Statistical Analysis 
For brain delivery of peptides and galbumin, the differences in the brains treated with or 
without BBB modulators were compared using ANOVA with Student–Newman–Keuls for 
determining the statistical significance. A p-value of less than 0.05 was used as a criterion for 
statistical significance. 
2.4 Results  
2.4.1 In Vivo Brain Delivery of Galbumin in Balb/c Mice as Detected by MRI 
The activity of cadherin peptides (i.e., HAV6, HAV4, cHAVc3, and ADTC5) to enhance the 
brain delivery of galbumin into the brain of Balb/c mice was evaluated. The HAV6, cHAVc3, and 
ADTC5 treatment groups showed a significant increase in the brain deposition of galbumin in the 
posterior, midbrain, anterior regions compared to those of vehicle (Figures 2.1A–D). The 
enhanced brain delivery of galbumin was observed as early as 3 min after the i.v. injection (Figures 
2.1B–D). In contrast, the HAV4 treatment group did not show an enhancement of galbumin brain 
deposition. From the AUC (Figure 2.1D), the levels galbumin enhancement were in the following 
order: posterior > midbrain > anterior. 
To evaluate the duration of BBB opening for large macromolecules, galbumin was delivered 
10 or 40 min after administration of HAV6 and ADTC5 peptides in a pretreatment experiment. 
Time-dependent galbumin brain depositions are shown in Figures 2.2A–D for 10-min pretreatment 
and in Figures 2.2A and 2.2E–G for 40-min pretreatment. The galbumin AUCs were also shown 
on immediate as well as 10- and 40-min pretreatment experiments (Figure 2.3). As previously 
shown, immediate delivery of galbumin with the HAV6 or ADTC5 peptide produced significant 
enhancements of galbumin brain deposition in all brain regions. After 10-min pretreatment with 
ADTC5, that there was still significant enhancement of brain deposition of galbumin while no 
68 
 
enhancement was observed with HAV6 pretreatment. Using 40-min pretreatment, there was no 
observed galbumin enhancement produced by ADTC5 or HAV6. 
2.4.2 In Vivo Brain Delivery of R800cw-cLABL in Balb/c Mice as Detected by NIRF Imaging 
The brain delivery of a 12-amino acid peptide, IRdye800cw-cLABL (MW = 2182.4 g/mol), 
was accomplished via i.v. administration in the presence and absence of ADTC5 (Figure 2.4). 
Twenty minutes after i.v. administration, the mice were sacrificed. NIRF imaging was used to 
detect peptide brain deposition. The labeled cLABL peptide delivered with ADTC5 has 
qualitatively higher brain fluorescence than that without ADTC5 (Figures 2.4A–B). 
Quantitatively, the brain-to-plasma ratio was used to determine the effect of ADTC5; the brain 
deposition of cLABL with ADTC5 was about 3.5-fold higher than that without ADTC5 (Figure 
2.4C, bottom panel). 
2.4.3 LC-MS/MS Method Development for Quantification of cIBR7 in Rat Brain 
For calculating the amounts of peptides in the rat brains, liquid chromatography and tandem 
mass spectroscopy conditions were optimized to achieve the best separation and quantification of 
cIBR7, ADTC5, and the IS peptides in the rat brain extracts. The standard solution for each peptide 
was infused into the mobile phase using a syringe; the dominant peaks were observed with mass-
to-charge ratios of m/z 776.5, 773.5, and 395.9 for cIBR7, ADTC5, and IS, respectively. MRM 
was used for each precursor ion to produce three respective transitions, including m/z 776.5  
m/z 70.2 for cIBR7; m/z 773.5  m/z 294.1 for ADTC5 and m/z 395.9  m/z 86 for IS using 
optimized collision energies of 120 V, 35 V, and 35 V, respectively. 





Selectivity of the method was evaluated by analyzing chromatograms of blank brain 
homogenate samples and blank brain homogenates spiked with cIBR7, ADTC5, and IS.  The 
results showed no endogenous interferences at the retention times of the three analytes (Figure 
2.5). The retention times for cIBR7, IS, and ADTC5 were 2.88 min, 3.80 min, and 6.10 min, 
respectively. 
Linearity, Accuracy, and Precision. 
 Calibration curves for cIBR7 and ADTC5 were prepared in concentrations ranging from 50 
to 500 ng/mL to determine the lowest limit of detection (LLOD) and intra-day and inter-day 
accuracy and precision (Table 2.3.). In this case, the peak area ratios of cIBR7-to-IS and ADTC5-
to-IS were plotted separately. Good linearity was observed for both cIBR7 and ADTC5 with R2 ≥ 
0.99. The LLOD for cIBR7 and ADTC5 were 15 ng/mL and 10 ng/mL, respectively. Intra-day and 
inter-day accuracy and precision were determined by analyzing samples at three concentration 
levels for %RSD and %RE (Table 2.3.). The %RSD and %RE values were less than 15% for intra-
day and inter-day for both analytes.  
 




%RSD %RE %RSD %RE 
cIBR7 50 10.1 14.1 9.6 11.2 
 
250 9.9 4.1 9.1 –1.9 
 
500 8.5 2.3 6.4 3.3 
ADTC5 50 7.4 6.6 12.4 3.7 
 
250 14.6 –3.3 6.7 2.1 
 
500 10.5 2.5 7.1 4.2 
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Stability and Extraction Recovery. 
The potential instability of cIBR7 and ADTC5 during the experiments was determined in three 
different peptide concentrations, temperatures, and storage conditions (Table 2.4.). The variability 
of each peptide in the brain extract was calculated to be less than 15% (%RSD) (Table 2.4.). The 
extraction recoveries of cIBR7 and ADTC5 from the brain homogenates were calculated by 
comparing the extracted and spiked samples. At three concentrations, the calculated mean 
recoveries for cIBR7 and ADTC5 were 90% and 92%, respectively (Table 2.5.). 
 






–20 °C Three freeze 
thaw cycles 
cIBR7 50 7.79 13.54 9.72 
 
250 9.48 1.90 5.72 
 
500 8.73 8.96 6.34 
ADTC5 50 12.18 9.18 13.12 
 
250 10.61 0.45 11.01 
 












2.4.5 In Vivo Brain Delivery of cIBR7 in Sprague-Dawley Rats 
The brain delivery of cIBR7 was evaluated in Sprague-Dawley rats following bolus i.v. 
injection of cIBR7 either alone or in combination with the cadherin peptide ADTC5. The amount 
of cIBR7 in the brain in the presence of ADTC5 was significantly higher (approximately four 
times) than that without ADTC5 (p = 0.013, Figure 2.6). In the presence of ADTC5, the average 
total amount of cIBR7 was 855 ± 171 ng/g brain while it was 213 ± 53 ng/g brain in the absence 
of ADTC5. Brain accumulation of cIBR7 was also determined in brain homogenates following 
capillary depletion to remove any cIBR7 within the brain vasculature. In this case, the ratios of 
cIBR7-to-IS without and with vasculature depletion were 0.133 and 0.128, respectively. This 
suggests that there is no difference between the two methods.  
 
 
Table 2.5.  Extraction recovery of cIBR7 and ADTC5 from rat brain 
homogenate 
Analytes Concentration (ng/mL) Extraction Recovery (%) 













The delivery of peptides and proteins including antibodies (MW~150 kDa) or Fab-fragment of 
antibodies (MW~50 kDa) into the brain for diagnosis and treatment of brain diseases had been a 
topic of great interest. However, success in delivering them to the brain has been very limited 
because they have physicochemical properties (e.g., size, hydrogen-bonding potential, and 
conformation) that prevent them from partitioning into cell membranes to cross the BBB.1 There 
is clearly a need to develop methods to deliver peptides and proteins into the brain. The ability to 
deliver functional peptides and proteins, including antibodies, into the brains of normal and 
diseased animals (i.e., mice and rats) would provide advantages in treating various brain 
pathologies and studying brain functions at the cellular level. Previously, cadherin peptides have 
been shown to improve in vivo delivery of small-to-large marker molecules, including 25 kDa 
IRdye-800cw PEG, into the brains of mice and/or rats.16-18, 20  In in vivo Balb/c mice, HAV6 
peptide also enhances the delivery of IRdye-800cw PEG in the lung, kidney, and small intestine.17 
It should be noted that the PEG molecule has physicochemical properties different from those of 
peptides and proteins in that they have a variety of functional groups as well as secondary or 
tertiary structures. 
The first aim was to determine brain delivery of a large protein, 65 kDa galbumin, using several 
known cadherin peptides (i.e., HAV6, HAV4, cHAVc3, or ADTC5) in Balb/c mice. Galbumin is 
a conjugate between albumin and Gd-complex; thus, it can be detected and quantified in the brains 
of living animals using MRI. Compared to vehicle control, ADTC5, HAV6, and cHAVc3 peptides 
significantly enhanced the delivery of galbumin into all three regions of the brain (i.e., posterior, 
midbrain, and anterior). The enhancement was immediate— within 3 min after administration of 
the modulator peptide with galbumin (Figure 2.1B–D). Our hypothesis is that cadherin peptides 
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open the intercellular junctions to create small, medium, and large pores in the paracellular 
pathways of the BBB as soon as the peptide is injected.18  It is interesting to find that HAV4 did 
not enhance galbumin brain delivery (Figure 2.1D); however, HAV4 did enhance brain delivery 
of Gd-DTPA.20 This suggests that HAV4 creates small pores but is unable to create the large pores 
in the intercellular junctions of the BBB required for delivery of macromolecules to the brain.  
Overall, ADTC5, HAV6, and cHAVc3 can effectively enhance the brain delivery of a protein as 
large as 65 kDa in Balb/c mice. 
The duration of the BBB opening created by HAV6 and ADTC5 peptides to allow large 
molecules to enter the brain is an important parameter for avoiding unwanted side effects of this 
method. The opening of BBB paracellular pathways for brain delivery should be tightly controlled 
to avoid BBB permeation of unwanted large molecules and immune cells (e.g., macrophages, T 
cells, and B cells) entering the brain. Therefore, the time-dependent effect of pretreatment using 
HAV6 or ADTC5 on the BBB permeation of galbumin was investigated. As expected, immediate 
treatment with HAV6 or ADTC5 peptide along with galbumin showed enhanced brain deposition 
of galbumin (Figure 2.3A). In contrast, ADTC5 but not HAV6 enhanced the brain delivery of 
galbumin when a 10-min peptide pretreatment experiment was conducted (Figure 2.3B). This 
indicates that the duration of the BBB opening provided by HAV6 peptide for a large molecule is 
less than 10 min and shorter than that produced by ADTC5. In contrast, the BBB opening for a 
large molecule by ADTC5 lasts longer than 10 min. After 40-min pretreatment, there was no 
enhancement of galbumin deposition in the brain by either peptide. This suggests that the duration 
of BBB opening for ADTC5 was longer than 10 min but shorter than 40 min. Overall, for both 




In previous studies, HAV6, HAV4, cHAVc3, and ADTC5 peptides significantly enhanced the 
brain delivery of a small molecular weight vasculature marker, Gd-DTPA (MW = 547.575 g/mol), 
in a dose-dependent manner.17, 18, 20 To determine the duration of BBB opening created by cadherin 
peptides for a small molecule, pretreatment studies were carried out using Gd-DTPA and detected 
by MRI. Following a 1-h pretreatment with peptide, linear HAV6 and HAV4 peptides did not aid 
the penetration of Gd-DTPA through the BBB, suggesting that the BBB opening created by these 
linear peptides lasts less than 1 h. In contrast, cyclic ADTC5 and cHAVc3 peptides create a BBB 
opening for Gd-DTPA delivery of more than 2 h but less than 4 h.18, 20 Therefore, cyclic ADTC5 
and cHAVc3 peptides created a longer lasting BBB opening than did linear HAV6 and HAV4 
peptides. The data suggest that both HAV6 and ADTC5 peptides create a longer duration of BBB 
opening for a small molecule (i.e., Gd-DTPA) than a large molecule (i.e., galbumin). To explain 
the observations in the pretreatment studies, it is proposed that cadherin peptides modulate the 
BBB by immediately creating small, medium, and large pores in the intercellular junctions. 
However, the large pores quickly collapse to medium and small pores and, finally, the medium 
pores collapse to small pores in the intercellular junctions of the BBB. 
To evaluate brain delivery of peptides, a 12-amino acid residue peptide, IRdye800cw-cLABL 
peptide, was delivered with ADTC5 in Balb/c mice. The peptide brain deposition was detected 
using NIRF imaging, which has an advantage in its ease of quantifying the molecule. The 
administration of ADTC5 peptide significantly enhanced brain delivery of cLABL peptide 
compared to control. The data suggest that the mechanism of transport of cLABL peptide was via 
passive diffusion through the paracellular pathway of the BBB. Although cLABL peptide could 
bind to and be internalized by ICAM-1 on the surface of BBB endothelial microvessels, the brain 
deposition of this peptide when delivered with vehicle was very low, suggesting that ICAM-1 
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receptor-mediated endocytosis was not involved (Figure 2.4). cLABL peptide was selected 
because it binds to ICAM-1 protein on the surface of epithelial, endothelial, and immune cells.  
ICAM-1 is upregulated during inflammation;22, 23 thus, it can be used as a target protein for labeled 
cLABL to detect upregulation of ICAM-1 during neuroinflammation. cLABL peptide is derived 
from the binding region of the I-domain of LFA-1 to the domain-1 (D1) of ICAM-1.28  It binds to 
ICAM-1 and inhibits LFA-1/ICAM-1-mediated T-cell adhesion to epithelial cells.29 In addition, it 
is also internalized by ICAM-1 in activated Molt-3 T cells.23  
The final aim is to develop a method to detect and quantify an intact peptide in the brain without 
the use of any radioactive, MRI, or NIRF label. cIBR7 peptide was selected for brain delivery 
using ADTC5 peptide in Sprague-Dawley rats; ADTC5 has not been evaluated in modulating the 
BBB of in rats in vivo.  Previously, ADTC5 peptide was shown to enhance brain delivery of 14C-
mannitol in an in situ rat brain perfusion model.18. In addition, HAV6 peptide has been shown to 
enhance brain delivery of an MRI contrast agent, Gd-DTPA, in in situ brain perfusion and in vivo 
in Sprague-Dawley rats.16 These results suggest that ADTC5 could also enhance the brain delivery 
of cIBR in rats. To detect the brain deposition of cIBR7, an extraction as well as a sensitive and 
selective LC-MS/MS method were developed to detect and quantify the delivered peptide in the 
rat brain. cIBR7 peptide was delivered in the presence of ADTC5 or control by injection via the 
jugular vein. After 10 min, the rat was sacrificed and the BBB was perfused with saline to remove 
potential residual peptides in the vascular endothelial cells to ensure accurate measurement of the 
analyte concentration in the brain. ADTC5 significantly enhanced the brain delivery of unlabeled 
cIBR7 peptide by as much as 4-fold (Figure 2.6, p = 0.013), and 855 ± 171 or 213 ± 53 ng/g brain 
of cIBR7 was detected when delivered using ADTC5 or vehicle, respectively. In summary, this 
study showed that ADTC5 enhanced the brain delivery of intact cIBR7 in Sprague-Dawley rats, 
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and that the extraction and LC-MS/MS detection methods were sensitive to quantified cIBR7 brain 
deposition. 
 cIBR7 peptide was selected because it binds to LFA-1 receptors on the surface of T cells and 
inhibits T-cell adhesion to Caco-2 cell monolayers.25 cIBR7 is a smaller analog of the parent cIBR 
peptide, which is derived from the D1 of ICAM-1. cIBR peptide has been shown to bind to the I-
domain of LFA-1 receptor.25, 26, 30 cIBR7 and cIBR peptides can be internalized by LFA-1 into the 
cytoplasmic domain of immune cells (i.e., T cells, H-60 leukemic cells);24, 31 therefore, labeled 
cIBR and cIBR7 peptides have the potential to detect LFA-1-expressing immune cells in the brain.  
It is interesting to find that the ADTC5 peptide was also detected in a lower amount (about 23 
ng/g brain) than cIBR7 (855 ng/g brain) in the brain although they were administered at almost 
similar dosage levels (i.e., 40 mg/kg cIBR7 and 30 mg/kg ADTC5). There are several potential 
reasons for this difference. First, ADTC5 could bind to cadherins in the adherens junctions of the 
BBB to lower the amount of free ADTC5 that would be available to penetrate the BBB. The half-
lives (t1/2) of plasma stabilities of ADTC5 and cIBR7 were 5.7 h and 2.8 h, respectively, suggesting 
that the low amount of ADTC5 in the brain was not due to its instability in plasma. Another 
alternative explanation is that cIBR7 and ADTC5 have vastly different pharmacokinetic and 
pharmacodynamic profiles; thus, further studies are needed to understand the difference in their 
brain depositions. 
This study developed and validated an extraction as well as a sensitive LC-MS/MS method to 
quantify the intact cIBR7, ADTC5, and IS in rat brains after in vivo studies. The results showed 
that cIBR7 peptide could be detected confidently as an intact molecule in the brain. The optimized 
extraction was very efficient, and it recovered higher than 90% of the intact cIBR7 and ADTC5 
peptides from the brain (Table 2.5.). The recoveries of cIBR7 and ADTC5 peptides from the brain 
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were accomplished by optimizing the homogenization medium, composition of extraction solvent, 
and the reconstitution solvent mixture. In addition, this study also confirmed our previous 
observation on brain delivery of labeled molecules (i.e., radioactive, IRdye, and Gd-DTPA). It also 
suggests that the detected labeled molecules could reasonably represent the intact molecules in the 
brain and are not due to detection of the label or molecular fragments of the parent molecules. 
IS peptide was designed as a reference molecule for the LC-MS/MS analysis to maximize the 
precision of peptide quantification in the brain and it has similar physicochemical properties as 
cIBR7 peptide. It was also used to account for errors and losses during sample handling and 
ionization during LC-MS/MS experiments. IS peptide was designed to have physicochemical 
properties similar to those of cIBR7 peptide. In this case, the Val6 residue in cIBR7 peptide was 
replaced with the Ile6 residue, and this simple change in IS provided a longer retention time (3.8 
min) for IS compared to cIBR7 peptide (2.88 min) in the C18 column of LC-MS/MS (Figure 2.5). 
The ADTC5 peptide was eluted at 6.10 min, which is 3.8 min later than IS peptide; therefore, all 
three peptides were well separated in the column. All three peptides (cIBR7, IS, ADTC5) were 
readily water soluble and, thus, no other additives or co-solvents were need for peptide 
reconstitution during the study. 
To improve the sensitivity of analyte detection, mass spectrometry (MS) parameters were 
initially optimized using a direct infusion of each analyte to the instrument, and the MRM of 
several stable transitions were optimized for each analyte. The best transition with the highest 
intensity was selected for each analyte. Then, the method validations for QC samples were carried 
out to determine selectivity, linearity, accuracy, precision, sensitivity, and stability over a range of 
concentrations in the calibration curve at 50–500 ng/mL following FDA guidelines.32 The results 
showed that the LC-MS/MS method was selective for all three analytes with no interferences. A 
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good linearity was achieved over a concentration range of 50–500 ng/mL for cIBR7 and ADTC5. 
Intra-day and inter-day precision and accuracy variability for both cIBR7 and ADTC5 were less 
than 15% (R.S.D and R.E) (Table 2.3.), suggesting that the MS method is accurate and precise. 
Variability (%R.S.D) for stability for both peptides was less than 15%, suggesting that the analytes 
are stable in brain extract under different conditions. Thus, the developed LC-MS/MS method was 
very sensitive and reliable for detecting the amount of delivered peptides in the brain. 
The hypothesis for the mechanism of action of cadherin peptides is that they bind in 
equilibrium fashion to the extracellular domain of E-cadherins to inhibit E-cadherin homophilic 
physical interactions (i.e., trans and/or cis interactions) among cadherins in the intercellular 
junctions in an equilibrium fashion.33 The physical nature of this inhibition is not expected to 
change the expression of E-cadherin on the cell surface. Incubation of MDCK cell monolayers (2–
4 h) with HAV6 peptide increased the total expression of E-cadherin in response to peptide 
modulation of the intercellular junction.14 However, it is still not clear whether the same 
phenomenon occurs in the BBB. Although E-cadherin is found on the epithelial cells and VE-
cadherin (cadherin-5) is found in the peripheral vascular endothelium,34 we found that proteins 
from bovine brain microvessel endothelial cells (BBMEC) react only with anti-E-cadherin 
antibody and not with anti-cadherin-5 and anti-N-cadherin.35 Abbruscato and Davis indicated that 
BBMEC monolayers also expressed E-cadherin.36 Vorbrodt et al. showed VE-cadherin in the rat 
endothelial BBB and a weak reaction with anti-E-cadherin;37 however, Vorbordt et al.38 and Rubin 
et al.34 suggested that VE-cadherin might not be associated with BBB function. Fluorescence-
labeled HAV decapeptide and anti-E-cadherin mAb can bind to the intercellular junctions of the 
BBMEC monolayers as punctate structures as observed by fluorescence microscopy.35 This 
labeled HAV peptide can also bind to single cells of BBMEC as detected by flow cytometry.35 
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HAV peptides and anti-E-cadherin mAb also inhibit cadherin-mediated homotypic single cell 
aggregation of BBMEC.39 Taken together, these results suggest that there is a potential role of E-
cadherin in the BBB. At this point, it is not clear whether these peptides also bind to VE-cadherin. 
To test whether cadherin peptides can bind to E-cadherin, the 15N-labeled extracellular-1 (EC1) 
domain of E-cadherin was expressed and was titrated with cadherin peptides (i.e., ADTC5, HAV6, 
and cHAVc3). These cadherin peptides caused changes in chemical shifts of several amino acids 
on the EC1 as observed using heteronuclear single quantum correlation (HSQC) NMR 
spectroscopy experiments.33 A combination of NMR spectroscopy and molecular docking 
experiments indicated that HAV6 and cHAVc3 peptides have a different binding site than that of 
ADTC5 peptide. The binding site of HAV6 and cHAVc3 is at residues Y36, I38, F77, S78, and 
I94 on the EC1 domain;33 in contrast, ADTC5 binds to residues I4, P5, P6, S8, and P10 on the N-
terminal β sheet of the EC1 domain. To put these results into perspective, the X-ray structure of 
C-cadherin was used to explain the potential mechanism of action of HAV- or ADT-peptides.  C-
cadherin could form cis- and trans-interactions. The cis-interactions are formed via the EC1 
domain of one molecule to the EC2 domain of a neighboring molecule on the same cell 
membranes.40 In contrast, the trans-interactions are formed by domain swapping of two N-termini 
of one EC1 domain from two opposing cell membranes. In the trans-interaction, the Trp residue 
at the N-terminus of one EC1 binds to a hydrophobic binding pocket of another EC1 domain from 
the opposing cell.40 Using a combination of the X-ray structure of C-cadherin and our NMR 
binding and molecular docking studies, we hypothesize that HAV peptides block the EC1-EC2 
cis-interactions of two cadherins from the same cell membranes to create greater porosity of the 
intercellular junctions of the BBB.33 In contrast, ADTC5 binds to the domain-swapping region of 
two EC1 domains for trans-interactions of E-cadherin from the opposing cell membranes. In 
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summary, the results suggest that HAV6 peptide disrupts the intercellular junctions of the BBB 
via inhibition of cis-cadherin interactions while ADTC5 modulates the BBB opening by inhibiting 
the trans-cadherin interactions.  
2.6 Conclusion 
This study has shown that cadherin peptides enhance the delivery of functional molecules such 
as a 65 kDa galbumin and peptides (i.e., cIBR7, cLABL). Both ADTC5 and HAV6 peptides create 
a short opening of the BBB for delivering a large molecule (i.e., galbumin) compared to a small 
molecule (e.g., Gd-DTPA). The intact cIBR7 peptide can be efficiently detected and quantified in 
the brain using LC-MS/MS. ADTC5 has been shown to modulate the BBB and enhance the brain 
delivery of molecules in mouse and rat models.  The results suggest that there is compatibility of 
quantifying molecules in the brain using MRI, NIRF, and LC-MS/MS. Finally, BBB modulation 
by cadherin peptides depends on (a) the type and dose of modulator peptide, (b) the timing of 
delivery between BBB modulator and the delivered molecule, and (c) the size of the delivered 
molecules. These results further support potential uses of cadherin peptides in delivering molecules 
to the brains of animal models of brain diseases for treatment, diagnosis, and evaluation of 











Figure 2.1  The effects of cadherin peptides (HAV6, HAV4, ADTC5, and cHAVc3) on enhancing 
brain delivery of 65 kDa galbumin as monitored MRI. (A) T1-weighted MR images of brain 
depositions of galbumin at 0 and 9 min time points when delivered with and without peptide. The 
depositions of galbumin were observed in the posterior, midbrain, and anterior regions as gray 
spots (see red arrows). (B–D) The time-dependent brain depositions of galbumin in the (B) 
posterior, (C) midbrain, and (D) anterior regions as monitored by MRI every 3 min over a 51-min 
imaging session. (E) The AUC of galbumin brain depositions when delivered with peptides or 
control vehicle. Star (*) represents statistical significant with p < 0.05 as evaluated using ANOVA 




















Figure 2.2  Comparison of 10-min and 40-min pretreatment with HAV6 or ADTC5 peptide on the 
brain depositions of galbumin. (A) T1-weighted MR image comparisons of brain depositions of 
galbumin after 10-min and 40-min pretreatment with HAV6 and ADTC5. The brain depositions 
of galbumin were observed as gray spots (see red arrows) in the posterior, midbrain, and anterior 
regions at 0 and 9 min time points using MRI. (B–D) Time-dependent brain depositions of 
galbumin observed at the (B) posterior, (C) midbrain, and (D) anterior regions when delivered 10 
min after HAV6 or ADTC5 administration. (E–G) Time-dependent brain depositions of galbumin 
observed at the (E) posterior, (F) midbrain, and (G) anterior regions when delivered 40 min after 
HAV6 or ADTC5 administration. Star (*) represents statistical significance with p < 0.05 as 







Figure 2.3  Comparisons of the AUC of galbumin brain deposition upon (A) immediate, (B) 10-
min, and (C) 40-min pretreatment with HAV6 and ADTC5 peptides. (A) Immediate delivery with 
HAV6 or ADTC5 peptide significantly enhanced brain deposition of galbumin in posterior, 
midbrain, and anterior regions. (B) With 10-min pretreatment, ADTC5 still significantly enhanced 
the delivery of galbumin while HAV6 did not. (C) With 40-min pretreatment, there was no 
enhancement in galbumin accumulation in the brain with either ADTC5 or HAV6 peptide. Star 
(*) represents statistical significant with p < 0.05 as evaluated using ANOVA with Student–
Newman–Keuls post hoc comparison of the means (n = 3). 
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Figure 2.4  The effect of ADTC5 peptide on increasing the brain deposition of IRdye800cw-
cLABL peptide after i.v. administration in Balb/c mice as detected by NIRF imaging. (A) The 
images of brain depositions of IRdye800cw-cLABL in different slices of the brain from anterior 
to posterior regions when delivered with vehicle (left) and ADTC5 (right). (B) The additive 
representation of brain depositions of IRdye800cw-cLABL when delivered with vehicle (left) or 
ADTC5 (right). (C) Comparison of brain-to-plasma ratios of IRdye800cw-cLABL peptide when 
administered with vehicle (control) and ADTC5. Star (*) indicates statistical significance with p < 




Figure 2.5  MRM chromatograms of brain extracts with (A) cIBR7 peptide (left) and blank (right), 
(B) IS peptide (left) and blank (right), and (C) ADTC5 peptide (left) and blank (right). The peptide 
separation was done using a Luna UPLC C18 column with 2.1 mm × 50 mm dimensions, particle 
size 5 μm, and pore size 100 Å (Phenomenex, Inc., Torrance, CA). The elution was done using a 
binary gradient mobile phase consisting of solvent A: H2O:formic acid (99.92:0.08) and solvent 




Figure 2.6  The effect of ADTC5 peptide on enhancing brain delivery of cIBR7 peptide in rats as 
detected by LC-MS/MS. cIBR7 (40 mg/kg) was delivered in the presence or absence of ADTC5 
(30 mg/kg). The rats were sacrificed after 10 minutes, and the whole brains were collected for 
analysis. The total amount of cIBR7 in rat brains after in vivo delivery via i.v. administration was 
significantly higher in the presence of ADTC5 compared to control with PBS treatment. Star (*) 
indicates a significant difference from the control study with p < 0.05. Error bars show the mean 
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Currently, protein drugs are a successful class of therapeutics for treating a wide variety of 
diseases such as cancers, infectious agents, genetic disorders, and autoimmune diseases (e.g., type-
1 diabetes (T1D), rheumatoid arthritis (RA), and multiple sclerosis (MS)). Protein therapeutics are 
normally developed with a specific and known mechanism of action and have reduced toxicity 
compared to small molecule drugs.1 Some proteins such as brain-derived neurotrophic factor 
(BDNF),2 nerve growth factor (NGF),3 and insulin-like growth factor 1 (IGF-1)4 have been 
investigated for inducing neuroregeneration in brain diseases such as MS and Alzheimer’s (AD). 
Unfortunately, previous attempts to deliver proteins via the systemic circulation have met with 
only limited success due to the presence of the blood-brain barrier (BBB), which prevents them 
from entering the brain.5-7 Monoclonal antibodies (mAbs), the  fastest growing type of drugs, have 
also been investigated to treat brain diseases.8 Several mAbs such as anti-Nogo-A,9 anti-LINGO-
1,10 sHIgM22,11 and VX15/250312 have been evaluated in clinical trials for inducing remyelination 
in MS patients; however, the clinical trials for most of these molecules were terminated due to 
their lack of efficacy in MS patients. A similar fate befell amyloid beta (A) mAbs, which failed 
to effectively treat AD patients. Although many reasons could contribute to these failures, one 
potential problem is their inability to cross the BBB effectively from the blood into the brain.   
The BBB is a selective barrier between the blood stream and the brain that prevents unwanted 
molecules from entering the brain.  Many drug molecules cannot readily cross the BBB because 
the molecules need to have appropriate physicochemical properties for crossing the BBB. Most 
molecules that can passively cross the BBB can be predicted using the Lipinski’s rule of five.13  
Because proteins do not satisfy this rule, BBB passive diffusion of proteins is very limited unless 
the protein has its own transporter on the endothelial microvessels for its transcytosis across into 
the brain. Therefore, there is a need to develop methods to improve protein delivery into the brain 
98 
 
in a non-invasive manner. Currently, many invasive ways such as intracerebral ventricular (ICV) 
delivery have been used to directly administer protein drugs into the brain in critical brain diseases. 
One of the limitations of the direct delivery method is the potential increase in brain infection and 
inflammation due to exposure to the outside environment. Currently, many non-invasive methods 
are being developed for enhancing brain drug delivery utilizing prodrug technology, receptor-
mediated transcytosis mechanisms,7 microbubble enhanced diagnostic ultrasound (MEUS) 
system,14 intranasal delivery,15 and BBB modulation.16, 17 A BBB modulation method called 
“osmotic BBB delivery” has been successfully used to deliver antitumor drugs for treating brain 
tumor patients.18 The osmotic BBB delivery method utilizes a hypertonic mannitol solution to 
disrupt the intercellular junctions of the BBB by shrinking the microvessel endothelial cells to 
allow anticancer drugs to passively penetrate the paracellular pathway of the BBB. Thus, the 
clinical success of the osmotic method provides impetus to investigate other ways to modulate the 
intercellular junctions of the BBB to improve brain delivery. 
One way to modulate the BBB intercellular junctions in a controlled and selective way is by 
inhibiting cadherin-cadherin interactions that mediate cell-cell adhesion. Thus, we designed 
cadherin peptides such as HAV6 and ADTC5 to inhibit cadherin-cadherin interactions in a 
dynamic and equilibrium fashion to increase the porosity of the paracellular pathways reversibly 
and allow molecules to cross the BBB from the blood stream into the brain. HAV6 peptide can 
enhance the in vivo brain delivery of small molecules (e.g., 14C-mannitol, 3H daunomycin, and 
gadopentetic acid (Gd-DTPA), and IRdye R800), and large molecules (e.g., 25 kDa IRdye800CW-
polyethylene glycol and 65 kDa galbumin).19-23 Similarly, ADTC5 peptide enhances brain delivery 
of 14C-mannitol, Gd-DTPA, 8–12 amino acid peptides, and galbumin.17, 22 
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In this study, the modulatory activities of HAV6 and ADTC5 were compared for brain delivery 
of different sizes of proteins such as 15 kDa lysozyme, 65 kDa albumin, 150 kDa IgG mAb, and 
220 kDa fibronectin. To accomplish this, the proteins were conjugated with IRdye800CW on 
lysine residues and the protein brain depositions were determined quantitatively using NIRF 
imaging. The quantification method was developed and validated using standard curves of 
homogenized brain containing the IRdye800CW-conjugate protein. The method of validation to 
generate quantitative data for delivered protein was carried out by determining the stability, 
accuracy, precision, and linear dynamic range of the quantitation method. This study provides the 
difference between the effectiveness of HAV6 and ADTC5 for delivering different sizes of 
proteins as well as the size limit of the protein that each peptide can deliver through the BBB. The 
effects of each peptide on depositions of each protein in different organs, including liver, kidney, 
heart, spleen and lungs, were also determined.  
 
3.2 Materials and Methods 
3.2.1 Chemicals, Reagents, and Animals.  
Gyros Protein Technologies, Inc. (Tucson, AZ) was used as a vendor to purchase amino acids 
and coupling reagents for the automated peptide synthesizer. IRdye-800CW-NHS ester and IRdye-
800CW Donkey anti-Goat IgG were purchased from LI-COR, Inc. (Lincoln, NE). Sigma Aldrich 
Chemical Company (St. Louis, MO) and Fisher Scientific, Inc. (Hampton, NH) were used as 
suppliers or proteins and reagents in this study. Protocols used for all animal studies have been 
approved by the Institutional Animal Care and Use Committee (IACUC) at The University of 
Kansas. All animals were cared by the Animal Care Unit personnel at The University of Kansas 




Table 3.1.  BBB Modulator Peptides 
Peptide Sequence Mass (Da) Exact Mass 
ADTC5 Cyclo(1,7)Ac-CDTPPVC-NH2 772 795.2778 (Na
+ Adduct) 
HAV6 Ac-SHAVSS-NH2 627 650.2869 (Na
+ Adduct) 
 
3.2.2 Peptide Synthesis and Purification.   
The synthesis of the linear and cyclic peptides (Table 3.1) were accomplished using a Tribute 
solid-phase peptide synthesizer from Gyros Protein Technologies, Inc. (Tucson, AZ). After peptide 
cleavage from the resin using TFA, the crude product was precipitated in cold diethyl ether. The 
formation of a disulfide bond in the cyclic ADTC5 peptide was accomplished by stirring the 
precursor linear peptide in bicarbonate buffer solution under air oxidation at pH 9.0 in high 
dilution. The cyclization reaction produced a high yield of the desired monomer with minor 
amounts of dimer and oligomer as side-products. The monomer was isolated from the mixture 
using a semi-preparative C18 column Waters XBridge C18 (19 mm × 250 mm, 5 μm particle size; 
Waters Corporation, Milford, MA)) in HPLC. The purity of each isolated fraction was determined 
by analytical HPLC using C18 column (Luna C18 (4.6 mm × 250 mm, 5 μm particle size, 100 Å; 
Phenomenex, Inc., Torrance, CA)). The identity of each peptide was confirmed by mass 
spectrometry. 
3.2.3 Conjugation of Proteins with IRdye-800CW-NHS Ester.   
Lysozyme, albumin, and fibronectin used in this study were conjugated with IRdye-800CW 
according to the manufacturer's instructions. Briefly, dyes were reacted with 1 mg/mL of protein 
in PBS with 10% potassium phosphate buffer, pH 9 (v/v) for 2 h at 25 °C. The resulting conjugates 
were purified using a spin column called Zeba Spin Desalting Column with 7 kDa molecular 
weight cut-off (Fisher Scientific, Inc. (Hampton, NH)). The purity of each conjugate was 
determined using SDS-PAGE, and the conjugate band was scanned (Excitation = 778 nm; 
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Emission = 794 nm) with an Odyssey CLx NIR scanner to ensure that there was no free IRdye-
800CW in the protein conjugate solution. Once any free dye was removed, the degree of labeling 
was determined using a UV spectrophotometer (Varian Cary 100, Agilent) to measure the 
fluorophore absorption and the protein absorbance at 280 nm, corrected for the fluorophore.  




)  =  
𝐴280 − (0.03 × 𝐴780)
𝜀𝑃𝑟𝑜𝑡𝑒𝑖𝑛
 × 𝑀𝑊𝑃𝑟𝑜𝑡𝑒𝑖𝑛 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
in which 0.03 is a correction factor for the absorbance of the IRDye-800CW at 280 nm (equal to 
3.0% of its absorbance at 780 nm). 𝜀𝑃𝑟𝑜𝑡𝑒𝑖𝑛 is the molar extinction coefficient of the protein and 
MWProtein is the molecular weight of the protein.  
3.2.4 NIRF Method to Quantify Protein Amount in the Brain.   
Preparation of Stock and Standard Curves.   
The stock solution for IRDye800CW protein (i.e., lysozyme, 70 µg/mL) was prepared and 
stored at –80 °C. The stock solution was later diluted with PBS to make the required standard 
solutions. To produce a standard calibration curve, 200 μL of blank brain homogenates was spiked 
with 10 µL standard solutions of various concentrations to yield a linear range from 0.5 to 50 
ng/mL. The same method was employed for the sample’s quality control (QC). 
Accuracy and Precision.   
For precision studies, IRDye-800CW-lysozyme was used. The intra-day and inter-day, 
accuracy and precision were calculated by analyzing replicates of spiked brain homogenates at 
three concentrations between 0.5 and 50 ng/mL. 
Evaluation of Method Stability.  
To evaluate the stability of the quantitative method, IRDye-800CW-labeled lysozyme was 
used in spiked brain homogenates under various temperature and storage conditions. Three sets of 
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samples were subjected to (a) room temperature for 6 h, (b) −20 °C for 24 h followed by unassisted 
thawing at room temperature, and (c) three freeze-thaw cycles between −20 °C and room 
temperature over a 24-h period. All stability studies were conducted at 0.5 to 50 ng/mL with three 
determinations for each. 
3.2.5 Brain Delivery IRdye800CW-labeled IgG mAb using ADTC5 in SJL/elite Mice.   
For initial evaluation of whether a cadherin peptide can deliver proteins into the brain, 
IRdye800CW donkey-anti-goat IgG mAb was administered via i.v. with and without ADTC5 
peptide in 5–8-week-old SJL/elite mice. Two groups of healthy SJL/elite mice were injected with 
(a) a mixture of IgG mAb (26.8 nmol/kg) and ADTC5 peptide (13 µmol/kg) (n = 5) and (b) IgG 
mAb alone (26.8 nmol/kg) (n = 4). After 15 min in the systemic circulation, the mice were 
euthanized using CO2 inhalation followed by brain perfusion using PBS to remove the remaining 
protein in the BBB microvasculature.  Next, the brains were isolated followed by NIRF imaging 
using Licor Odyssey CLx (Licor, Lincoln, NE). Eight optical sections were taken at 0.5 mm 
increments beginning from the bottom surface of the brain to a depth of 4 mm.  The optical sections 
were summed to yield a fluorescence intensity value per each brain. 
3.2.6 Comparison of HAV6 and ADTC5 in Delivering Various Sizes of Proteins into C57BL/6 
Mice.   
The BBB modulatory activities of ADTC5 and HAV6 to enhance brain delivery of 
IRdyeR800CW-labeled lysozyme, albumin, IgG mAb, and fibronectin were compared in C57BL 
mice. The proteins with or without 13 µmol/kg HAV6 or ADTC5 were administered via tail vein 
injection. For lysozyme, the delivered doses were 21.6 and 54 nmol/kg. For albumin, IgG mAb, 
and fibronectin, the dose used was 21.6 nmol/kg. After 15 min, the mice were sacrificed followed 
by cardiac perfusion with PBS with 0.5% Tween-20. The brain and other organs such as lung, 
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heart, spleen, liver and kidney were harvested and rinsed with PBS. Protein depositions in the brain 
and other organs were quantified by NIRF imaging using an Odyssey CLx NIRF scanner.  
A second quantification method was done using brain homogenates. In this case, the brains 
were homogenized in 2.0 mL PBS by mechanical disruption and 200 µL of homogenized brain (n 
= 8) was aliquoted to a 96-well plate followed by quantification using the Odyssey CLx scanner. 
The signal intensity was compared to calibration curve and normalized to brain weight and 
homogenate volume.  
3.2.7 Capillary Depletion Method.   
Parallel capillary depletion experiments were performed as described by Triguero et al.24 to 
ensure that there was no trapping of the delivered molecules in the BBB microvessel endothelial 
cells. Brain homogenates dosed with IRdye800CW-labeled protein were mixed together and 
divided into two sets. A 500 μL set of homogenates was mixed with 500 μL of PBS while another 
set of 500 μL homogenates was mixed with 500 μL of 26% dextran solution. Both sets were 
centrifuged at 5,400 g for 15 min at 4 °C and 200 μL of supernatant was collected for analysis 
using the Odyssey CLx scanner. 
3.2.8 Statistical Analysis.   
For brain delivery of various sized molecules, the differences in the brains treated with or 
without BBB modulators were compared using ANOVA with Student–Newman-Keuls for 




3.3.1 Peptide Synthesis and Purification.   
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The Fmoc solid-phase synthesis method was used to make linear precursor to ADTC5 and 
HAV6 peptides. ADTC5 was cyclized using air oxidation in a high dilution solution at pH 9.0 to 
give mostly the desired cyclic monomer.  A semi-preparative HPLC with C18 column was used 
to purify both ADTC5 and HAV6 peptides with >96% purity of each peptide as determined by 
C18 column in analytical HPLC. The mass spectra for both purified peptides show exact masses 
of 650.2869 Da for sodium adduct of HAV6 and 795.2778 Da for sodium adduct of ADTC5 (Table 
3.1).  
3.3.2 Synthesis and Purification of IRdye800CW-labeled Proteins.  
To make IRdye800CW-labeled lysozyme, albumin, or fibronectin, IRdye800CW-NHS was 
reacted to free amino groups of the respective protein to form stable conjugates. To purify the 
protein conjugates, the excess of IRdye800CW-NHS was removed from the reaction mixture using 
a Pierce Zeba desalting spin column with a cut-off molecular weight of 7 kDa. The purified 
conjugates were evaluated with SDS-PAGE scanned with an Odyssey CLx NIR imager. Lysozyme 
and albumin conjugates showed a single band while fibronectin had a faint lower fragment band; 
all proteins have the appropriate mass without unreacted IRdye (Figure 3.1). The final protein 
concentrations for lysozyme, albumin, and fibronectin were determined to be 1.35, 1.68, 2.30 
mg/mL, respectively.   
3.3.3 Initial Brain Delivery of IRDye800CW-IgG mAb by ADTC5 in SJL/Elite Mice.   
In this study, IgG mAb was administered via i.v. in SJL/elite mice in the absence or presence 
of ADTC5 peptide. Prior to injection, IgG mAb identity was evaluated using SDS-PAGE gel and 
showed a major band at ~150 kDa with very light bands for ~100 kDa heavy and ~50 kDa light 
chains (data not shown). There was no observation of the band for IRDye800CW alone. After 
delivery, the brain scans of mice treated with IgG mAb alone showed very low NIRF image in 
eight different levels of brain scans (n = 4) (Figure 3.2A). In contrast, the mouse brains 
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administered IgG mAb with ADTC5 showed strong NIRF signals on eight different brain scan 
levels (n = 5) (Figure 3.2A). Quantitative accumulation of NIRF signals from all scan levels 
indicated that the brains from mice treated with IgG mAb + ADTC5 had a significantly higher 
signal intensity than those of mice treated with IgG mAb alone (Figure 3.2B).  In summary, 
ADTC5 increases the brain delivery of IgG mAb in C57BL/6 mice. 
3.3.4 Method Development and Validation of NIRF Quantification 
Linearity, Accuracy, and Precision.  
The lowest limit of detection (LLOD) and intra-day as well as inter-day precision and accuracy 
were determined using a calibration curve generated with concentrations from 0.5 to 50 ng/mL 
(Table 3.2). The calibration curve was generated by plotting concentrations of standard vs. NIRF 
intensity from the Odyssey CLx imaging system (Figure 3.3).  The resulting standard curve has 
good linearity with R2 ≥ 0.98 and LLOD of 0.3 ng/mL. Intra-day and inter-day accuracy as well 
as precision were determined by analyzing samples at three different concentrations to obtain 
%RSD and %RE (Table 3.2). The acceptable analytical method was determined when the %RSD 
and %RE values were less than 15%. 
 
 
Stability Assay.   




%RSD %RE %RSD %RE 
0.5 15.1 7.1 10.5 6.4 
5.0 4.6 -2.8 3.4 5.8 
50.0 2.8 5.4 3.8 1.6 
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The stability of the analyte during evaluation was investigated using IRDye800CW-lysozyme 
in three concentrations at two temperatures and a freeze-thaw condition (Table 3.3). In different 
analyte concentrations in the brain extracts, the %RSA was less than 15% at room temperature for 
6 h. The RSD was higher than 15% under the other two conditions (a) −20 °C for 24 h followed 
by unassisted thawing at room temperature and (b) after three freeze-thaw cycles between −20 °C 
and room temperature over a 24-h period. 




Room Temp. (6 h) –20 C (24 h) Three freeze-thaw cycles 
0.5 7.7 16.2 23.1 
5.0 5.4 18.5 8.5 




Table 3.4. Quantitative Amounts of Proteins in the Brain 
Protein Group pmol/g brain 
Lysozyme Control 0 ± 0 
 HAV6 8.3 ± 2.5 
 ADTC5 37.8 ± 7.1 
Albumin Control 11.8 ± 1.0 
 HAV6 15.5 ± 3.1 
 ADTC5 40.7 ± 7.4 
IgG mAb Control 4.0 ± 0.4 
 HAV6 3.4 ± 0.5 
 ADTC5 13.3 ± 0.7 
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3.3.5 Comparison of HAV6 and ADTC5 in Enhancing Brain Delivery of Various Proteins. 
In this study, the activities of HAV6 and ADTC5 peptides to deliver various sized proteins 
(i.e., lysozyme, albumin, IgG mAb, and fibronectin) in C57BL/6 mice were compared in a 
quantitative manner. The intensities of lysozymes at various concentrations in the brain 
homogenates are shown in Figure 3.2A. Figure 3.2A also shows the examples of NIRF scans of 
brain homogenates from animals treated with lysozyme alone, lysozyme + HAV6, and lysozyme 
+ ADTC5. The resulting calibration curve generated from 0.5 to 50 ng/mL of lysozyme produced 
a linear curve with R2 ≥ 0.99 (Figure 3.2B). Similar calibration curves were generated for albumin 
and IgG mAb. The amount of protein in the brain was determined by interpolation of NIRF 
intensity of the brain homogenate into the standard curve.  
3.3.6 Brain Delivery of 15 kDa Lysozyme and Peripheral Organ Distributions.   
The first delivery of lysozyme was carried out at a dose of 21.6 nmol/kg with 13 µmol/kg of 
HAV6 or ADTC5 peptide, and no significant improvement was observed in the brain compared to 
lysozyme alone (data not shown). Next, the dose of lysozyme was increased to 54 nmol/kg with 
13 µmol/kg of HAV6 or ADTC5 peptide (Figure 3.4). Through visual observation, the NIRF brain 
images of mice treated with HAV6 + lysozyme and ADTC5 + lysozyme appeared to show higher 
intensity than those treated with lysozyme alone (Figure 3.4A). The NIRF intensity of the ADTC5 
group was higher than that of HAV6 group. Quantitatively, the average amount of lysozyme in the 
ADTC5 group (37.8 ± 7.1 pmol/g brain) was significantly higher than that in the HAV6 group (8.3 
± 2.5 pmol/g brain, p <0.05) (Figure 3.4B, Table 3.4). The lysozyme amounts in the brains of 
both peptide groups were higher than that of control group, which was below the detection limits. 
The results suggest that ADTC5 is a better BBB modulator than HAV6. To ensure that the brain 
perfusion procedure eliminated any residual molecule in the BBB microvessels, the brain capillary 
depletion was carried out using the brain homogenates. The capillary depleted samples were 
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compared to non-depleted samples. The difference between the capillary depleted and non-
depleted samples was less than 1.9%, indicating the that the perfusion method was satisfactory in 
removing almost all the labeled protein from the brain capillaries. 
The effects of HAV6 and ADTC5 in lysozyme distributions in kidney, lung, heart, spleen, and 
liver were also determined (Figures 3.4C & D). Visually, the most intense NIRF images were in 
the kidney in all three groups, with the highest image intensity on ADTC5 group. Quantitative data 
confirmed that lysozyme deposition in the kidney was the highest in the ADTC5-treated group, 
followed by the HAV6-treated group and control. It is not surprising that the lysozyme undergoes 
glomerular filtration in the kidney because of its molecular weight being lower than 65 kDa. 
3.3.7 Brain Delivery of 65 kDa Albumin and Peripheral Organ Distributions.   
To evaluate molecules larger than lysozyme, 65 kDa albumin was delivered using HAV6 and 
ADTC5 in C57BL/6 mice compared to control (i.e., albumin alone) (Figures 3.5A, B). The 
calibration curve was generated with 0.5 to 500 ng/mL labeled albumin in brain homogenates to 
generate a good linearity with R2 ≥ 0.98. The mice treated with albumin + ADTC5 showed a 
significantly higher albumin deposition (40.7 ± 7.4 pmol/g brain) compared to albumin alone (11.8 
± 1.0 pmol/g; p < 0.05). Although it was not significant, the HAV6 group showed a trend of 
enhanced brain with brain deposition of 15.5 ± 3.1 pmol/g compared to control (11.8 ± 1.0 µmol/g 
brain (p = 0.20)).  These data also showed that ADTC5 was a better BBB modulator than HAV6 
in delivering albumin. 
The effects of HAV6 and ADTC5 peptides in the distribution of albumin in different organs 
were evaluated using NIRF quantitative imaging (Figures 3.5C, D). The data indicated that HAV6 
(p = 0.04) and ADTC5 (p = 0.04) significantly enhanced the distributions of albumin into the liver 
compared to control. There was no significant difference in albumin depositions between the liver 
ADTC5 group and the HAV6 group (p = 0.15). Although the deposition in spleen is lower than in 
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liver, the HAV5 and ADTC5 groups both enhanced the deposition of albumin in the spleen 
compared to control. 
3.3.8 Brain Delivery of 150 kDa IgG mAb and Peripheral Organ Distributions.   
Because many mAbs have been utilized as therapeutics, there is high interest in improving 
their brain delivery. For quantitative determinations, a calibration curve for mAb was prepared 
with concentrations ranging from 10 to 200 ng/mL of IRDye800CW-IgG mAb spiked into blank 
brain homogenates. The calibration curve showed good linearity with R2 ≥ 0.99. As in the previous 
study in SJL/elite, NIRF imaging signals from mAb in the brains of ADTC5+mAb-treated mice 
were higher than those of mAb-treated mice in C57BL/6 mice (Figure 3.6A). The amounts of 
mAb in the brains of mice treated with ADTC5+mAb (13.3 ± 0.7 pmol/g) were significantly higher 
compared to those of HAV6+mAb (3.42 ± 0.5 pmol/g; p < 0.05) and mAb alone (4.0 ± 0.4 pmol/g; 
p < 0.05) (Figure 3.6B).   HAV6 peptide was not able to deliver mAb (p > 0.05) compared to 
control mAb (Figure 3.6B). The enhancement of mAb brain deposition by ADTC5 is about three 
times that of control. ADTC5 showed a trend to enhance the distribution of mAb into liver 
compared to HAV6- (p = 0.06) and control-treated animals (p = 0.06) (Figures 3.6C, D). The 
distributions of mAb in HAV6- and control-treated animals were about the same (p = 0.54).   
3.3.9 Brain Delivery of 220 kDa Fibronectin and Peripheral Organ Distributions.   
To find the larger limit of pore sizes made by ADTC5 peptide, the brain delivery of fibronectin 
(220 kDa) was evaluated in the presence and absence of ADTC5 (Figure 3.7A, B). HAV6 was not 
investigated for delivering 220 kDa fibronectin because it cannot deliver 150 kDa mAb. ADTC5 
did not enhance brain delivery of 220 kDa fibronectin because the NIRF signals for the ADTC5 + 
fibronectin group (35.498 ± 3.001 × 103A.U.) was not different than that of fibronectin alone group 
(33.026 ± 2.080 × 103 A.U.) (Figure 3.7A, B). The distributions of fibronectin were mostly in the 
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Proteins have been successfully used to treat many diseases, and some proteins such as mAbs 
have been evaluated to treat brain diseases such as brain tumors (e.g., glioblastoma) as well as 
neurodegenerative diseases, including Alzheimer’s, multiple sclerosis (MS), and Parkinson’s. 
Unfortunately, many proteins, including mAbs that were developed to treat brain diseases, have 
failed in clinical trials. One of the reasons is the inefficiency of proteins to cross the BBB 
sufficiently to exude their activities in the brain. The BBB plays a vital role in restricting unwanted 
molecules from reaching the brain for regulating the internal environment of the brain.25  Various 
approaches have been investigated to deliver drugs to the brain following systemic administration. 
Our approach is to use cadherin peptides to modulate cadherin-cadherin interactions to create 
larger pores in the intercellular junctions to allow proteins to enter the brain in a non-invasive 
manner. In an initial proof-of-concept, ADTC5 peptide was used to deliver IRDye800CW-IgG 
mAb in SJL/elite mice.  The brains of animals treated with ADTC5+IgG mAb had high NIRF 
intensities while very low NIRF intensities were observed in the brains of animals treated with IgG 
mAb alone (Figure 3.2). With the initial data, the next step was to compare the effectiveness of 
HAV6 and ADTC5 peptides in enhancing the brain delivery of various sized proteins such as 15 
kDa lysozyme, 65 kDa albumin, 150 kDa IgG mAb, and 220 kDa fibronectin. It was proposed that 
each peptide has different BBB modulatory activities in delivering different sizes of proteins. In 
addition, each peptide creates a maximum pore size opening in the paracellular pathway so there 
is a cut-off size of proteins that can pass through the BBB. Thus, it was necessary to develop a 
rapid method to quantitatively determine the amount of protein delivered into the brain. Finally, 
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the effects of each peptide on the distributions of i.v. administered proteins in organs other than 
the brain were evaluated. 
Prior to evaluating the delivery of various sized proteins, 150 kDa IR800-IRdye-IgG mAb was 
administered via i.v. tail-vein injection to SJL/elite mice in the presence (n = 5) and absence (n = 
4) of ADTC5 peptide (13 µmol/kg) and allowed to circulate for 15 min (Figure 3.2). The brains 
of mice administered mAb alone (n = 4) showed very low background-intensity NIRF (Figure 3.2 
A, left images), suggesting that little or no mAb entered the brain. The brains of mice administered 
mAb + ADTC5 showed high NIRF intensity, suggesting that ADTC5 enhanced mAb brain 
delivery (Figure 3.2A, right images). The mean pixel NIRF intensity was significantly higher (4.7 
times higher) in mAb + ADTC5-treated mice compared to those from mice injected with mAb 
alone (Figure 3.2B). Because IgG mAb can be delivered to the brain, a NIRF quantitative method 
was developed to determine the amounts of delivered proteins in the brain per gram of brain 
(pmol/g brain).  
To develop a simple, rapid, and quantitative method to determine the amount delivered protein 
in the brain, NIRF imaging method was used in this study. Calibration curves were developed for 
each delivered protein. Homogenized brain samples were spiked with different concentrations of 
standard labeled proteins, and fluorescence intensities were determined using with the Odyssey 
CLx scanner (Figure 3.3A). Good linearity for the calibration curve was achieved with R2 ≥ 0.98. 
The amount of delivered protein in the brain in pmol/g brain can be determined by interpolating 
the NIRF intensity from the brain homogenate into the calibration curve (Figure 3.3B). To validate 
the NIRF method, QC samples of IRDye800CW-lysozyme were analyzed to determine the 
stability, accuracy, and precision over the range of the calibration curve following FDA guidelines. 
Intra-day and inter-day precision and accuracy variability were found to be less than 15% (R.S.D 
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and R.E) (Table 3.2), suggesting that the NIRF method was accurate and precise. The stability of 
the labeled protein in brain homogenates was evaluated under different conditions; only the brain 
homogenates that were kept at room temperature for 6 h showed %R.S.D. values under 15%. It 
was found that the other conditions for the analytes were not stable in brain extracts, including −20 
°C for 24 h followed by unassisted thawing at room temperature as well as after three freeze-thaw 
cycles between −20 °C and room temperature over a 24-h period. Therefore, all the analyses were 
done within the time frame of 6 h. With a linear calibration curve and lower %RSD and %RE 
values for precision and accuracy, the developed NIRF imaging method was very sensitive and 
reliable for detecting and quantifying the delivered labeled proteins. 
To carry out the in vivo brain delivery experiments, the protein was administered via i.v. with 
and without BBB modulators (i.e., HAV6 or ADTC5) followed by allowing the delivered protein 
to remain in the systemic circulation for 15 min. The animal was then euthanized, followed by 
perfusion of the brain capillaries to eliminate the remaining protein in the blood vessels. The brain 
was isolated and homogenized followed by transferring the homogenates into a 96-well plate. The 
intensity of NIRF from the protein in the homogenate was detected by scanning with the Odyssey 
CLx scanner and the intensity was normalized by weight of the brain. Previously, the NIRF method 
has been used to quantify study IRDye800CW mAb distribution ex vivo in tissues. The method 
was deemed to be accurate and sensitive when compared to a commonly used reference method 
called gamma ray quantification.26 Comparison of NIRF and gamma ray quantification data sets 
using the Bland-Altman method concluded that the results from quantification using NIRF are the 
same as those using the gamma ray method.26 
Comparison between the activities of ADTC5 and HAV6 in modulating the BBB provides 
insight into the paracellular pore size openings and potential use of each peptide in delivering 
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various sized proteins into the brain. In this study, ADTC5 peptide can effectively improve the 
delivery of lysozyme, albumin, and IgG mAb into the brains compared to control; however, 
ADTC5 cannot enhance the delivery of 220 kDa fibronectin. Using a 15-min circulation time, the 
results suggest that ADTC5 created pores large enough to allow proteins with the largest size 
between 150 and 220 kDa to penetrate the BBB.  Using the same experimental conditions, HAV6 
significantly enhanced the brain delivery of lysozyme but not albumin and IgG mAb, indicating 
that the pore-size opening in the BBB paracellular pathways was smaller than that crated by 
ADTC5. In summary, the modulatory activity of ADTC5 is distinctly different than that of HAV6; 
thus, this difference can be used to deliver selected groups of proteins, depending on the 
therapeutic need. 
Although lysozyme is smaller than albumin and IgG mAb, no observable lysozyme was found 
in the brains when delivered with a dose of 21.6 nmol/kg along with HAV6 or ADTC5 at 13 
µmol/kg (data not shown). In contrast, the lysozyme was observed in the brain when it was 
delivered at a higher dose (54 nmol/kg) along with HAV6 or ADTC5 at 13 µmol/kg (Figure 3.4). 
The depositions of lysozyme were significantly higher in the brain when delivered with ADTC5 
compared to HAV6 peptide (Figure 3.4A, B). In addition, the amounts of lysozyme in the brains 
were slightly lower than albumin when delivered using HAV6 or ADTC5, although the 
administered dose of lysozyme was higher than that of albumin (Table 3.4). One of the 
explanations for the need of a higher dose of lysozyme is the rapid clearance of lysozyme in the 
kidney because of glomerular filtration. The depositions of lysozyme in the kidney were higher 
than in other organs (i.e., heart, lung, spleen, and liver) (Figures 3.4C, D). It is interesting to find 
that ADTC5-treated mice have significantly enhanced deposition of lysozyme in the kidney 
compared to control, suggesting that ADTC5 affected cadherin interactions in the kidney. In 
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contrast, HAV6 did not significantly enhance the amount of lysozyme in the kidney compared to 
control. Previously, low molecular weight proteins (LMWP) have been shown to be suitable 
carriers for specific renal drug delivery due to their high accumulation in kidney. They are freely 
filtered in the glomerulus and subsequently accumulate specifically in the proximal tubular cells, 
utilizing receptor-mediated endocytosis.27, 28  Conjugation of the antihypertensive drug captopril 
and the analgesic drug naproxen to lysozyme resulted in a 6–to–60-fold enriched accumulation in 
the kidney.29 Taken together, the results suggest that the brain delivery of lysozyme or other 
proteins is influenced by its kidney clearance, resulting in a decrease in systemic concentration for 
penetration into the brain. 
Albumin has been explored as a drug carrier where several strategies have been developed 
including various forms of physical and covalent binding (e.g., albumin-drug and peptide 
conjugate) as well as drug encapsulation in albumin nanoparticles.15, 30-32 Falcone et al. showed an 
improved brain uptake of radioactive-labeled albumin in CD1 mice when administered via 
intranasal delivery;15 however, there is no clear mechanism for the way that albumin can be 
transported into the brain. The paracellular brain delivery of albumin using ADTC5 and HAV6 
was compared and quantified by NIRF imaging. It showed a significantly higher brain deposition 
of albumin in the presence of ADTC5 compared to control and HAV6 peptide (Figure 3.5A, B). 
In contrast, the HAV6-treated group did not have significantly higher brain deposition of albumin 
compared to a control group (i.e., albumin alone). Although, using the current conditions, HAV6 
peptide did not enhance the delivery of albumin, our previous data showed that HAV6 peptide 
could significantly enhance the delivery of 65 kDa galbumin (a gadolinium complex conjugated 
to albumin) into the brain compared to control as detected using magnetic resonance imaging 
(MRI) in living mice.22 In the MRI study, the dose of HAV6 peptide (10 μmol/kg) was similar to 
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the current study dose, but the dose of galbumin in the MRI study was 27 times higher (600 
nmol/kg) than the dose (21.6 nmol/kg) in the current study.22 The circulation time of the MRI study 
was 51 min compared to 15 min in the current study. Therefore, the high dose of galbumin provides 
a more pronounce amount of galbumin in the brain as detected by MRI. The MRI studies suggested 
that ADTC5 was a better enhancer of galbumin brain delivery than HAV6, and this previous 
finding was confirmed by the current findings when ADTC5 was compared to HAV6 in delivering 
IRdye800CW-albumin (Table 3.4). ADTC5 significantly enhanced brain deposition of albumin 
while HAV6 did not (Figure 3.5A, B). In summary, the data indicated that ADTC5 is a better 
modulator for large proteins compared to HAV6 peptide, and the dose of delivered molecules 
influences the transport of molecule across the BBB. The results also suggest that both peptides 
created different populations of small, medium, and large pore sizes, but ADTC5 created a higher 
population of large pores than did HAV6 peptide. Thus, ADTC5 allows larger molecules to 
penetrate the BBB compared to HAV6.  
The enhancement of IgG mAb brain delivery using ADTC5 or HAV6 was evaluated. Due to 
their size, passive diffusion of IgG mAb across the BBB was very minimal and normally antibody 
brain concentrations are 1,000 times lower than in the bloodstream. Here, brain delivery of IgG 
mAb was significantly improved by ADTC5 in C57BL/6 mice but not by HAV6 (Figure 3.5A, B; 
Table 3.4). The results support a proposal that each peptide has a limit of size cut-off for delivering 
various sized proteins. In the future, the effects of circulation time and multiple injections of 
proteins will be explored in the future to determine the optimal delivery protocol for mAbs or other 
proteins. This method can also be used to rapidly screen the modulatory activity of new peptides 
in improving brain protein delivery. 
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The data from mice treated with both peptides suggest that there is a cut-off size for each 
peptide in delivering molecules to the brain. ADTC5 peptide did not enhance the delivery of 
fibronectin (220 kDa), suggesting that the molecular size cut-off for ADTC5 is 220 kDa. The 
molecular cut-off is important to limit the number of unwanted molecules or proteins from 
penetrating the BBB and potentially generating side effects. Another important characteristic for 
BBB modulation is the duration of the BBB modulation created by HAV6 and ADTC5 peptides 
to prevent long-term opening that would allow unwanted large molecules to enter the brain. 
Previously, ADTC5 and HAV6 have been shown to modulate the BBB immediately, allowing 
delivered molecules to enter the brain within 3 min.17, 20, 22 The modulation of the BBB by HAV6 
within the span of less than 1 h would allow a small molecule such as Gd-DTPA (547 Da) to enter 
the brain.20 In contrast, HAV6 did not allow 65 kDa galbumin to enter the brain after a 10-min 
delay between delivery of HAV6 and galbumin.22 Pretreatment of mice with ADTC5 produced a 
longer opening (between 2 and 4 h) than with HAV6 for a small molecule such as Gd-DTPA.17 
However, with large molecules (e.g., galbumin, 65 kDa), ADTC5 showed an enhancement only 
after a 10-min delay of pretreatment with peptide but no enhancement after a 40-min 
pretreatment.22 The duration of paracellular pathways opening of the BBB created by ADTC5 is 
longer for all types of molecules compared to HAV6.22 For ADTC5 peptide, the BBB opening 
lasted for a smaller time frame for a large molecule than for a small molecule. More importantly, 
the BBB seals back to its original position after the clearance of the peptide, which is a crucial 
parameter in delivering selected proteins into the brain.17, 22 Our previous studies using 
transmission electron microscopy showed that after modulation of the BBB with cadherin peptides 
(i.e., ADTC5) there are no detectable differences in the morphology of brain microvessel 
endothelial cells compared to that of unmodulated control.17 We also found that vesicular activity 
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appeared to be similar in both vehicle and peptide-treated mice.17  Taken together, these results 
suggest that each peptide creates different mechanism of modulatory activity that translate to 
generation of various pore sizes in the intercellular junctions. One hypothesis is that each peptide 
creates sub-populations of small, medium, and large pores in the intercellular junctions and the 
large pores collapse to medium and small pores and the medium pores collapse to small pores in a 
time-dependent manner. It is proposed that the large pores collapse faster than medium pores; this 
will be tested in the future. 
Evaluations of ADTC5 and HAV6 peptides in other organs are necessary to assess their 
applicability as drug delivery enhancers because cadherin-mediated cell-cell adhesion is present 
in other organs (i.e., kidney, lung, spleen, liver, and heart). Modulation of cadherin-cadherin 
interactions in other organs may lead to increased permeability to other parts of the body, which 
can lead to off-target site delivery as well as side effects in the host. Therefore, it is necessary to 
find out the effects of each peptide on the deposition of delivered proteins in other organs. The 
results could also be utilized to design better and selective BBB modulators that will not affect 
other organs. As mentioned previously, 15 kDa lysozyme is highly accumulated in the kidney 
compared to other organs (i.e., heart, spleen, lungs, and liver) for all three groups (i.e., control, 
HAV6-, and ADTC5-treated groups). ADTC5-treated groups had significantly higher lysozyme 
kidney deposition compared to control while HAV6-treated groups did not. ADTC5-treated groups 
for all other proteins larger than lysozyme have higher deposition in the liver compared to control 
but lower deposition in kidney, spleen, lung, and heart. For HAV6-treated groups, only albumin 
has higher deposition in the liver compared to control, and there were no significant differences in 
other organs. There was no enhancement of fibronectin deposition in the liver of ADTC5-treated 
groups. In summary, ADTC5 has influenced in depositions of delivered proteins in kidney or liver 
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while HAV6 has influence in protein deposition in kidney and liver for lysozyme and albumin, 
respectively. 
The BBB modulatory activities of ADTC5 and HAV6 peptide were due their binding to 
cadherin and inhibiting cadherin-cadherin interactions in the intercellular junctions of the BBB. 
Both HAV6 and ADTC5 peptides bind to the EC1 domain of E-cadherin at different binding sites 
as determined using heteronuclear single quantum correlation (HSQC) NMR spectroscopy and 
molecular docking experiments. ADTC5 binds to I4, P5, P6, S8, and P10 residues on the N-
terminal β sheet of the EC1 domain while HAV6 binds to the Y36, I38, F77, S78, and I94 residues 
of the EC1 domain.33 Using the X-ray structure of C-cadherin as a model, it is proposed that HAV6 
peptide binds to the EC1 domain and blocks the EC1-EC2 cis-cadherin derived from two cadherins 
on the same cell membranes.34, 35 In contrast, ADTC5 bind to the domain-swapping region of EC1 
and inhibits EC1-EC1 trans-cadherin interactions from the opposite cells.33 Because ADTC5 
blocks trans-cadherin interactions, its effects on the intercellular junctions presumably are more 
pronounced than those of HAV6, which inhibits cis-cadherin interactions. Experimentally, our 
data for all proteins indicate that ADTC5 has higher modulatory activity and longer duration of 




ADTC5 can deliver 15 kDa lysozyme, 65 kDa albumin, and 150 kDa mAb IgG but not 220 
kDa into the brain of C57BL/6 mice while HAV6 can enhance only brain delivery of lysozyme. 
Each peptide creates cut-off size of proteins that can be delivered into the brain. HAV6 peptide 
only allows molecule less than 65 kDa to enter the brain while ADTC5 can deliver molecules of 
less than 220 kDa to enter the brain. ADTC5 and HAV6 peptides could enhance the depositions 
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of delivered proteins in the kidney and liver. Finally, the NIRF imaging method is a very useful 










Figure 3.1  The SDS PAGE gels IRdye800CW-labeled (A) 15 kDa Lysozyme, (B) 65 kDa 
Albumin, (C) 150kDa IgG mAb, and (D) 220 kDa Fibronectin that are imaged using Odyssey CLx 
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Figure 3.2  The effect of ADTC5 (13 µmol/kg) on improving the brain delivery of IRdye800CW-
IgG mAb (21.6 nmol/kg) in SJL/elite mice. (A) The image shows whole brain fluorescent of mice 
that received IRDye800cw-IgG mAb alone (left; n = 4) and IRDye800cw-IgG mAb + ADTC5 
(right; n = 5). (B) Mean fluorescence intensity of IRDye800cw-IgG mAb for quantitative 
comparison of NIRF signals between mice that received IRDye800cw-IgG mAb+ADTC5 vs. 
IRDye800cw-IgG mAb alone; asterisk (*) indicates a significant difference from the control group 












Figure 3.3  Development of the quantification method and standard curve for IRdye800CW-
lysozyme using NIRF image of brain homogenates in a 96-well plate scanned using Odyssey CLx 
imaging system. (A) Examples of scanned images of brain homogenates from various 
concentrations of standard samples as well as samples form HAV6- and ADTC5-treated mice. 
Each well was scanned to get the NIRF intensity. (B) An example of calibration curve for lysozyme 
(R = 0.988) was generated by plotting the concentrations of spiked standard against the 
fluorescence intensity. The concentrations of lysozyme in the brains of HAV6- and ADTC5-
treated mice were determined by interpolating the fluorescence intensity in the standard curve.  
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Figure 3.4  Qualitative and quantitative comparisons of IRdye800CW-lysozyme (64 nmol/kg) 
depositions in the brain and other organs when administered alone and along with HAV6 and 
ADTC5 peptides (13 µmol/kg). (A) Qualitative comparison of NIRF brain images from control, 
HAV-, and ADTC5-treated animals. (B) Quantitative comparisons of lysozyme brain depositions 
in pmol/g brain for control, HAV6-, and ADTC5-treated mice. (C) A representative of lysozyme 
depositions in heart, kidney, lung, spleen, and liver. (D) Comparisons of lysozyme depositions in 
of various organs using tissue NIRF signal intensities. Asterisk (*) indicates a significant 
difference from the control group with ADTC5 group with p < 0.05. Error bars show the mean ± 
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Figure 3.5  Qualitative and quantitative comparisons of IRdye800CW-albumin (21.6 nmol/kg) 
depositions in the brain and other organs when administered alone and along with HAV6 and 
ADTC5 peptides (13 µmol/kg). (A) Qualitative comparison of NIRF brain images from control, 
HAV-, and ADTC5-treated animals. (B) Quantitative comparisons of albumin brain depositions 
in pmol/g brain for control, HAV6-, and ADTC5-treated mice. (C) A representative of lysozyme 
depositions in heart, kidney, lung, spleen, and liver. (D) Comparisons of albumin depositions in of 
various organs using tissue NIRF signal intensities. Asterisk (*) indicates a significant difference 
from the control group with ADTC5 group with p < 0.05. Error bars show the mean ± SE from 
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Figure 3.6  Qualitative and quantitative comparisons of IRdye800CW-IgG mAb (21.6 nmol/kg) 
depositions in the brain and other organs when administered alone and along with HAV6 and 
ADTC5 peptides (13 µmol/kg). (A) Qualitative comparison of NIRF brain images from control, 
HAV-, and ADTC5-treated animals. (B) Quantitative comparisons of IgG mAb brain depositions 
in pmol/g brain for control, HAV6-, and ADTC5-treated mice. (C) A representative of IgG mAb 
depositions in heart, kidney, lung, spleen, and liver. (D) Comparisons of IgG mAb depositions in 
of various organs using tissue NIRF signal intensities. Asterisk (*) indicates a significant 
difference from the control group with ADTC5 group with p < 0.05. Error bars show the mean ± 
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Figure 3.7  Qualitative and quantitative comparisons of IRdye800CW-fibronectin (21.6 nmol/kg) 
depositions in the brain and other organs when administered alone and along with ADTC5 peptide 
(13 µmol/kg). (A) Qualitative comparison of NIRF brain images from control, HAV-, and 
ADTC5-treated animals. (B) NIRF intensities of brain homogenates from ADTC5-treated and 
control mice.  (C) A representative of fibronectin depositions in heart, kidney, lung, spleen, and 
liver. (D) Comparisons of fibronectin depositions in of various organs using tissue NIRF signal 
intensities. Asterisk (*) indicates a significant difference from the control group with ADTC5 
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Improving In Vivo Brain Delivery of Monoclonal Antibody Using 





Insufficient delivery of drugs across the blood-brain barrier (BBB) has become the major 
challenge in diagnosing and treating brain-related diseases.1-3 Many large molecule therapeutics 
such as neurotrophic factors, enzymes, and antibodies are being developed to treat brain disorders 
such as neurodegenerative diseases (e.g., multiple sclerosis (MS) and Alzheimer’s disease (AD)) 
and brain tumors (e.g., glioblastoma and medulloblastoma); however, the BBB is one of their 
major hurdles for entering the brain. Most large molecules such as monoclonal antibodies (mAbs) 
have low efficiency to enter the brain because any molecule that crosses the BBB requires 
appropriate physicochemical properties or a specific transporter. The BBB is a very selective 
barrier whose main function is to regulate the passage of nutrients into brain and provide brain 
protection against toxic compounds and pathogens. The transcellular pathway, which many 
hydrophobic drugs utilize to cross the BBB, is also limited to molecules with physicochemical 
properties that at least satisfy Lipinski’s rule of five.4 Even if a molecule satisfies Lipinski’s rule, 
it can still be prevented from crossing the BBB by efflux pumps.2  
The paracellular pathway, where a drug molecule can pass through the intercellular junction, 
is also limited to small ions and hydrophilic molecules with hydrodynamic radius <11 Å.2 This is 
due to the presence of tight junctions between two opposing cellular membranes. Therefore, large 
hydrophilic molecules such as peptides and proteins normally cannot passively diffuse through the 
paracellular pathway. On the other hand, a selected number of peptides and proteins (e.g., insulin, 
transferrin) can cross the BBB via the transcellular pathway because they have specific transporter 
systems (e.g., insulin and transferrin receptors).3, 5-9 Currently, many neurotrophic factors such as 
nerve growth factor (NGF)10 and brain-derived neurotrophic factor (BDNF)11 have been 
investigated for treating neurodegenerative diseases such as MS and AD. Unfortunately, as with 
other proteins, the brain delivery of NGF or BDNF is still very challenging. Therefore, there is an 
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urgent need to develop methods that are safe and effective for improving delivery of proteins and 
peptides into the brain. 
Several attempts have been made to overcome this challenge using various invasive and non-
invasive methods. Intracerebral ventricular (ICV) delivery has currently been used as an invasive 
injection technique where drug substances are administered directly into the cerebrospinal fluid in 
cerebral ventricles. Alternatively, many non-invasive methods have been investigated in vivo with 
various levels of successes using receptor-mediated drug delivery systems, liposomes, 
microbubble-enhanced diagnostic ultrasound (MEUS), and nanoparticles.12-14 The most successful 
non-invasive method for delivering drugs to brain tumor patients is the osmotic BBB disruption, 
which utilizes a mannitol hypertonic solution to shrink the vascular endothelial cells and increase 
the porosity of the paracellular pathway to improve permeation of antitumor drugs from the blood 
into the brain.15-17 Following in the footsteps of the osmotic BBB method, we designed cadherin 
peptides (e.g., HAV6 and ADTC5) that modulate cadherin-cadherin interactions in the adherens 
junctions to increase porosity of the BBB paracellular pathways to allow molecules to cross from 
the bloodstream into the brain.1, 2 The proposed mechanism is that cadherin peptides inhibit 
cadherin-mediated cell-cell adhesion in a specific, dynamic, and equilibrium fashion. Both HAV6 
and ADTC5 peptides were derived from the extracellular-1 (EC-1) domain of E-cadherin and, 
collectively, they have been shown to increase the brain delivery of various molecules, including 
paracellular markers (e.g., 14C-mannitol, 25 kDa IRdye800CW-polyethylene glycols or PEG), 
anticancer drugs (e.g., 3H-daunomycin, Glu-CPT, adenanthin), efflux pump substrates (e.g., 
rhodamine 800 (R800), 3H daunomycin), magnetic resonance imaging (MRI)-enhancing agents 
(e.g., gadopentetic acid or Gd-DTPA), peptides (e.g., IRdye800cw-cLABL and cIBR7), and 





The goal of this study was to design and synthesize novel cyclic peptides derived from HAV6 
and ADTC5 peptides to improve their BBB modulatory activity by forming a peptide bond from 
the N- to C-termini. The hypothesis is that the formation of N- to C-termini cyclic peptides 
increases backbone rigidity of the peptide to improve binding affinity for the EC1 domain cadherin 
as well as improving plasma stability of the cyclic peptide compared to its parent linear peptide. 
Previously, cHAVc3 and ADTC5 cyclic peptides were formed using a disulfide bond between two 
Cys residues at the N- and C-termini; these cyclic peptides have enhanced BBB modulatory 
activity and plasma stability compared to their parent linear peptides.19, 20 However, a disulfide 
bond in cyclic peptides can be reduced by glutathione in plasma to form a linear peptide that may 
have lower biological activity. Thus, we designed stable N- to C-termini cyclic peptides (i.e., 
HAVN1 and HAVN2) derived from HAV6 and cyclic ADTHAV peptide utilizing a combination 
of sequences from ADT and HAV peptides (Table 4.1). A cyclization procedure was developed 
to make N- to C-termini cyclic peptides using acetonitrile for easy solvent evaporation compared 
to using dimethylformamide (DMF), which is difficult to evaporate or remove (Figure 4.1). The 
Table 4.1. Peptide Names and Peptide Sequences 
Peptide Sequence Mass (Da) Exact Mass (Da) 
Cyclic ADTC5 Cyclo(1,7)Ac-CDTPPVC-NH2 772 795.2778 (+ Na
+) 
Linear ADTHAV Ac-TPPVSHAV-NH2 847 848.4602 
Cyclic ADTHAV  Cyclo(1,8)TPPVSHAV 788 789.9167 
Linear HAV6 Ac-SHAVSS-NH2 627 650.2869 (+ Na
+)  
Cyclic HAVN1 Cyclo(1,6)SHAVSS 568 569.2352 
Cyclic HAVN2 Cyclo(1,5)SHAVS 481 482.2286 
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BBB modulatory activities of new cyclic peptides were compared to current linear HAV6 and 
cyclic ADTC5 peptides in vivo by brain delivery of an IRDye 800CW-labeled IgG mAb in 
C57BL/6 mice. The effects of the new cyclic peptides on IgG mAb depositions in other organs 
such as liver, kidney, spleen, lung, and heart were also determined to assess potential off-target 
tissue effects or side effects of these cadherin peptides. 
4.2. Materials and Methods 
4.2.1. Chemicals, Reagents, and Animals 
Most of the reagents (e.g., trifluoro acetic acid (TFA), hydrogen gas, Pd/C catalyst, 
triisopropylsilane (TIPS), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), 
diisopropyl ethyl amine (DIEA)) and solvents (e.g., acetonitrile, methanol) were purchased from 
Sigma Aldrich Chemical Company (St. Louis, MO) and Fisher Scientific Inc. (Hampton, NH). All 
amino acids for peptide synthesis were purchased from Gyros Protein Technologies Inc. (Tucson, 
AZ). IRDye800CW Donkey anti-Goat IgG for brain delivery was purchased from LI-COR Inc. 
(Lincoln, NE). All protocols used for animal studies have been approved by the Institutional 
Animal Care and Use Committee (IACUC) at The University of Kansas. The animals were 
maintained in the Animal Care Unit with free access to food and water. 
4.2.2. Peptide Synthesis and Purification 
A Tribute solid-phase peptide synthesizer (Gyros Protein Technologies, Inc., Tucson, AZ) with 
Fmoc chemistry was used to synthesize all linear peptide precursors (Table 4.1). The HAV6 and 
linear precursors for cyclic ADTC5 peptide were synthesized using amide resin and were cleaved 
from the resin with a cocktail mixture of 89% TFA:5% phenol:3% H2O:3% TIPS. The linear 
precursors for N- to C-termini cyclic peptides (i.e., HAVN1, HAVN2, and ADTHAV) were 
synthesized using Fmoc-Val-Wang resin. The carboxylic acid and alcohol groups on the side 
chains were protected with benzyl groups. The peptides were cleaved using 94% TFA: 3% H2O: 
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3% TIPS cocktail solution. The TFA solutions of linear HAV6, ADTC5, ADTHAV were added 
into cold diethyl ether to precipitate the peptide. In contrast, the cleavage solutions of linear 
HAVN1 and HAVN2 were directly concentrated by rotary evaporator to yield the crude peptides 
that were further lyophilized. 
To form cyclic ADTC5, a very low concentration of linear peptide precursor without any 
protecting groups was dissolved in bicarbonate buffer solution at pH 9.0, and then, the solution 
was bubbled with air to oxidize the two thiol groups in the Cys residues to form a disulfide bond. 
The end-result produced cyclic ADTC5 peptide in a monomeric form with low side products as 
dimers, trimers, and oligomers. The desired monomer was purified by semi-preparative HPLC 
using C18 column Waters XBridge C18 (19 mm × 250 mm, 5 μm particle size; Waters 
Corporation, Milford, MA). The mobile phase consisted of solvents (A) H2O: ACN: TFA 
(94.9:5:0.1) and (B) acetonitrile with a gradient of 40% B (0 min), 40–100% B (17 min), 100% B 
(2 min), 100–40% B (2 min), and 40% B (6 min). Before combining the collected fractions, each 
fraction was evaluated using analytical HPLC using a C18 column (Luna C18, 4.6 mm × 250 mm, 
5 μm particle size, 100 Å; Phenomenex, Inc., Torrance, CA) to check for purity, and the pure 
fractions were pooled, concentrated, and lyophilized.  
The N- to C-termini cyclizations to produce cyclic ADTHAV, HAVN1, and HAVN2 were 
carried out in solution phase (Figure 4.1). In this case, the acid and alcohol functional groups on 
the peptide were protected with benzyl ester and ether groups that were removed after cyclization. 
The optimized molar ratio of peptide: HATU: DIEA for the cyclization reaction was 1:2:4, and the 
cyclization reaction was done in dilute solution (~ 6.0 mM of peptide) in acetonitrile (ACN). In 
this case, three separate solutions were prepared: (1) 6.3 mmol peptide in 50 mL of acetonitrile, 
(2) 12.6 mmol HATU in 50 mL acetonitrile, and (3) 25.2 mmol DIEA in 1 L of acetonitrile. Then 
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the solutions of peptide and HATU were both added slowly from two different peristaltic pumps 
into the DIEA solution over 4 h, and the mixture was stirred overnight. The completion time for 
cyclization reaction was monitored using mass spectrometry every 4 h to observe the 
disappearance of the linear precursor and the appearance of the cyclic peptide with the loss of 18 
amu from removal of one molecule of H2O. After confirming the complete formation of the cyclic 
peptide, the acetonitrile was removed by rotary evaporator. A C18 semi-preparative HPLC column 
was used to isolate the cyclic peptide and the pure peptide was lyophilized. The cyclic peptide was 
dissolved in methanol and subjected to hydrogenation reaction under balloon pressure in the 
presence of Pd/C catalyst overnight to remove benzyl ester and ether protecting groups. The final 
product was purified by semi-preparative HPLC, and the identity of the cyclic peptide was 
confirmed using mass spectrometry (Table 4.1).  
4.2.3. EC1 Protein Expression and Purification 
For studies of peptide binding to the EC1 domain of E-cadherin, the EC1 domain protein was 
expressed and purified using our previously published protocol.24, 25 The protein has 138 amino 
acids with 110 residues from the EC1 domain and an additional 28 residues at the C-terminus from 
the interface between the EC1 and EC2 domains. The N-terminus contains an added Streptag I 
sequence (WSHPQFEK) connected to the IEGR sequence as an interface to the N-terminus of the 
EC1 domain, and the IEGR sequence can be cleaved by Factor Xa enzyme. The protein was 
purified using an affinity Strep Tactin II column (5.0 × 0.6 cm; GE Healthcare Life Sciences, 
Pittsburgh, PA). The protein cDNA (BlueHeron, Bothell, WA) was subcloned into pASK-IBA6 
plasmid (Genosys, Woodland, TX) and 2 μL of cDNA vector was mixed into 50 μL of BL21 cells 
followed by incubation for 30 min in ice.  Then, the cells were warmed for 30 s in water bath at 
42°C to allow cDNA to enter the cells; that was followed by a cooling period in an ice bath for 3 
min. The cell suspension was then added with 200 μL of SOC medium and the resulting mixture 
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was shaken at 250 rpm and 37 °C for 1 h. The mixture was aliquoted (50 and 100 μL) into different 
agar plates followed by incubation for 12–16 h at 37 °C. Several colonies were selected from either 
a 50- or 100-μL-plate and incubated into 10 mL of LB medium (10 g NaCl, 10 g peptone, 5 g 
yeast, and up to 1 L of dd H2O) followed by addition of ampicillin solution (10 μL of 100 mg/mL). 
The mixture was incubated overnight at 37 °C followed by its addition into 1 L of LB medium, 
which was incubated until the cell density was 0.6–0.8 at OD 600 nm. Cell growth was stimulated 
by adding 50 μL anhydrotetracycline (2 mg/mL, Promega Inc., Madison, WI) to start expressing 
the EC1 domain followed by incubation for 4 h at 30°C. The resulting cells were harvested by 
centrifugation at 10000–12000 rpm, and cell pellets were immediately stored at –80°C. 
Prior to the SPR experiment, the EC1-containing cells were taken from the –80°C freezer and 
subjected to a lysing procedure using the French press in 25 mL binding buffer (100 mM Tris, 150 
mM NaCl, 1 M EDTA, 1 mM DTT, 0.02% NaN3, pH 8). The lysed cells were centrifuged at 14000 
rpm and 4 °C for 1 h to remove cell debris. The supernatant was isolated and filtered through a 0.2 
μm sterile filter. Then, the filtrate was centrifuged using Amicon Ultra tubes (EMD Millipore, 
Billerica, MA) with 3,000 Da molecular weight cutoff to concentrate the EC1 protein. The 
concentrated EC1 was purified using a StrepTactin II column. The column was equilibrated and 
washed with binding buffer before and after protein solution exposure to the column at 5 mL/min 
flow rate. Pure protein was eluted from the column using an elution buffer containing 2.5 mM 
desthiobiotin at a flow rate of 2 mL/min. Tris-Bis SDS-PAGE (4–12%) was used to check the 
purity of the protein fractions from the affinity column.  The protein concentration was determined 
using a UV spectrophotometer at 280 nm with molar absorptivity of 19480 M-1 cm-1. 
4.2.4. Surface Plasmon Resonance 
The binding affinity of cyclic ADTC5 and cyclic ADTHAV peptides to the EC1 protein was 
determined using surface plasmon resonance (SPR) (OpenSPR instrument, Nicoya Lifesciences, 
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Waterloo, Canada) equipped with a 100 μL loading loop at 25 °C in a constant flow rate of 25 
μL/min. The EC1 protein was injected into a streptavidin sensor chip with a running buffer (100 
mM Tris HCl, 150 mM NaCl, 1% BSA, and 0.05% Tween20 at pH 7.4) to immobilize the protein. 
Next, different concentrations of peptide were injected to evaluate their binding process followed 
by washing with running buffer. The concentration range used for ADTC5 was from 6.25 µM to 
50 µM while the concentration range for cyclic ADTHAV was between 550 nM and 2 µM. After 
peptide injection, 100 µM of HCl was injected to completely dissociate the complex and regenerate 
the sensor. Data analysis was done using Trace Drawer software (Ridgeview Instruments AB) as 
recommended by the manufacturer. Kinetic parameters were calculated using global analysis by 
fitting the data to a One-to-One binding model.  
4.2.5 In Vivo Delivery of IRdye800CW IgG mAb   
The activity of each peptide in enhancing BBB penetration was evaluated by delivering 
IRdye800CW Donkey anti-Goat IgG mAb in C57BL/6 mice; the amounts of mAb in the brain 
were determined using an NIRF imaging method.  IgG mAb (21.6 nmol/kg) along with 13 µmol/kg 
peptide was administered via tail vein, and mAb was administered alone as a control. After the 
delivered molecules were circulating for 15 min, the mice were sacrificed; then, a mixture of PBS 
with 0.5% Tween20 was administered for cardiac perfusion to remove the blood and delivered 
molecules in the brain microvessels. The brain and other organs such as lung, heart, spleen, liver, 
and kidney were harvested and rinsed with PBS. The isolated organs were scanned with Odyssey® 
CLx for mAb quantification. 
The brain deposition of IgG mAb was also quantified by NIRF imaging in brain homogenates. 
The isolated brains were mechanically homogenized in 2.0 mL PBS. To make the standard 
solutions, IRDye800CW IgG mAb stock solution (70 µg/mL) was prepared and it was diluted with 
various amounts of PBS. To generate a calibration curve, the homogenized mixture (200 µL; n = 
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8) was aliquoted out to a 96-well plate. 10 µL of solutions with various concentrations of IgG mAb 
were added to the blank brain homogenates to make standard spiked homogenates with a range of 
10–200 ng/mL IgG mAb. Then the wells were scanned using the Odyssey® CLx scanner, and the 
signal intensities vs. concentrations of mAb per gram brain were used to generate a calibration 
curve. 
4.2.6. Statistical Analysis  
ANOVA with Student–Newman–Keuls was used to compare the data for determining 
statistical significance for IgG mAb depositions in the brains. The p-value of less than 0.05 was 
used as a criterion for a significant difference in data comparison. 
4.3. Results 
4.3.1. Peptide Synthesis and Purification 
The solid-phase peptide synthesizer was used to generate all peptides used in this study and 
the synthesis was done using Fmoc amino acids. A high yield of crude peptide was normally found 
for peptide synthesis. The cyclization reaction to make cyclic ADTC5 peptide was uneventful and 
it generated mostly a monomeric cyclic peptide. The syntheses of N- to C-termini cyclic peptides 
were done by a combination of solid-phase and solution-phase synthetic methods (Figure 4.1). As 
an example, the linear ADTHAV as a precursor to a cyclic peptide was synthesized using solid 
phase peptide synthesis and the side chains of the Asp, Ser, and Thr residues were protected with 
benzyl ester and ether protecting groups. These protecting groups were maintained during the 
cleavage reaction to remove the peptide from the resin. After a semi-preparative HPLC 
purification, the isolated product was considered acceptable when it has >96% purity as 
determined by analytical HPLC with a C18 column. The cyclization was done in acetonitrile in 
high dilution to favor intramolecular peptide bond formation and to prevent formation of dimers, 
trimers, and oligomers. The major product was a monomeric cyclic peptide. The exact mass of 
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each N- to C-termini cyclic peptide is shown in Table 4.1, where the molecular mass of the cyclic 
peptide was 18 amu (– H2O) less than the precursor linear peptide.  
 
4.3.2. Surface Plasmon Resonance 
Binding properties between cyclic ADTC5 or ADTHAV peptide to the immobilized EC1 
domain protein on streptavidin chips were analyzed using SPR (Figures 4.2 and 4.3). The results 
showed that the dissociation constants (KD) for ADTC5 and cyclic ADTHAV were 26.8 µM and 
0.114 µM, respectively (Table 4.2), suggesting that cyclic ADTHAV has tighter binding to the 
EC1 domain than does ADTC5. 
Table 4.2.  Dissociation Constant (KD) for ADTC5 and ADTHAV Cyclic Peptide 
Peptide Kon (M-1.S-1) Koff (S-1) KD (µM) 
ADTC5 5.33 x 10
3 1.64 x 10-1 26.8 
Cyclic ADTHAV 5.47 x 10
4 6.23 x 10-3 0.114 
 
4.3.3. In Vivo Delivery of IRdye 800CW IgG mAb 
The new cyclic peptides were compared to ADTC5 and HAV6 peptides by evaluating their 
activities in delivering IgG mAb into the brains of C57BL/6 mice. As a negative control, IgG mAb 
was delivered in PBS without peptide. Previously, ADTC5 has been shown to improve brain 
delivery of IgG mAb, which can serve as a positive control. Cyclic HAV peptides (i.e., HAVN1, 
HAVN2) and linear HAV6 were evaluated to test whether the formation of cyclic peptides could 
improve their BBB modulatory activity. Cyclic ADTHAV peptide was formed via a combination 
of ADTC5 and HAV6 sequences to test the potential additive activity of the two sequences. 
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Because ADTC5 and HAV6 bind to two different binding sites on the EC1 domain, it is proposed 
that cyclic ADTHAV has two different binding sites on the EC1 domain.  
A calibration curve was generated to determine the amount of IgG mAb in the brain by spiking 
blank brain homogenates with a concentration range from 10 to 200 ng/mL and a good linearity 
with R2 ≥ 0.99 was achieved. As previously found, HAV6 did not enhance brain delivery of IgG 
mAb compared to control, i.e., IgG mAb alone (Figure 4.4, p > 0.05). while IgG mAb brain 
delivery was significantly enhanced by cyclic HAVN1 and HAVN2 peptides compared to HAV6 
and control (Figure 4.4). These results indicate that cyclic peptide formation increases BBB 
modulatory activity of HAV peptide. The average amounts of IgG mAb in the brains of HAV6-
treated and control animals were 4.0 ± 0.4 and 3.4 ± 0.5 pmol/g brain, respectively. In contrast, 
the average amounts of mAb in the brains of cyclic HAVN1- and HAVN2-treated mice were 8.6 
± 0.5 and 8.8 ± 0.6 pmol/g brain, respectively (Table 4.3). The BBB modulatory activities of 
ADTC5, linear ADTHAV, and cyclic ADTHAV (Figure 4.5; Table 4.3) were also compared to 
control. The brain delivery of IgG mAb by linear ADTHAV, cyclic ADTHAV, and ADTC5 was 
significantly better than the PBS control. The average brain depositions of IgG mAb were 11.8 ± 
0.5, 15.7 ± 0.8, and 13.3 ± 0.7 pmol/g brain for linear ADTHAV, cyclic ADTHAV, and ADTC5, 
respectively. 
The effects of peptides in the deposition of IgG mAb in other organs such as liver, kidney, 
heart, spleen and lungs were compared to control. There was no significant difference in IgG mAb 
deposition in other organs for HAV6-, HAVN1- and HAVN2-treated animals compared to control 
animals (Figure 4.6). These results suggest that these BBB-modulating peptides do not have a 
significant impact on other organs (Figure 4.6). In contrast, ADTC5 and linear ADTHAV peptides 
have significant effects on the distribution of IgG mAb in the heart and kidney when compared to 
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control (Figure 4.7). Moreover, there were significant increases in depositions of IgG mAb in 
liver, kidney, spleen, and lungs for cyclic ADTHAV peptide when compared to control (Figure 
4.7). 
 
Table 4.3. Brain Delivery of IgG mAb with BBB Modulating Peptides 
Peptide pmol/g brain 
Control 4.0 ± 0.4 
HAV6 3.4 ± 0.5 
HAVN1 8.6 ± 0.5 
HAVN2 8.8 ± 0.6 
ADTC5 13.3 ± 0.7 
Liner ADTHAV  11.8 ± 0.5 
Cyclic ADTHAV 15.7 ± 0.8 
 
4.4. Discussion                             
Treating brain diseases has become a challenge as it is difficult to deliver drugs through the 
BBB into the brain. As many approaches to solve this problem have failed clinically, it is important 
to investigate new methods to improve brain delivery of molecules for diagnosing and treating 
brain diseases. This study was focused on designing, synthesizing, and evaluating new cyclic 
peptides for modulating the BBB to increase paracellular protein delivery into the brain. Our 
previous studies showed that ADTC5 and HAV6 peptides modulate the paracellular pathways of 
the BBB and increase the permeation of small marker or drug molecules, peptides and proteins 
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into the brain.19-23 The aim of this study was to design and synthesize more potent and selective 
cyclic peptides derived from ADTC5 and HAV6 sequences and evaluate their BBB modulatory 
effects in delivering IgG mAb to the brain. First, cyclic HAVN1 and HAVN2 peptides derived 
from linear HAV6 sequence were synthesized by N- to C-termini cyclization. The hypothesis is 
that cyclic peptides are more selective and conformationally more stable than the parent linear 
peptides. Second, a combination of ADT and HAV6 sequences was implemented in linear and 
cyclic ADTHAV peptides. The hypothesis is that the combined sequence and cyclization can 
enhance the BBB modulatory activity of the parent peptides. Thus, linear and cyclic ADTHAV 
peptides were compared to ADTC5 in delivering IgG mAb into the brains of C57BL/6 mice. 
Previously, the formation of cyclic peptides has been shown to improve biological activity and 
plasma stability of peptides. Many cyclization methods have been utilized to improve 
conformational stability and binding properties of peptides to their respective target receptor(s). 
Various covalent bonds have been utilized to form cyclic peptides by linking two ends of the 
peptide with an amide, lactone, ether, thioether, or disulfide bond using. The cyclization can be 
formed via backbone-to-backbone (or N-to-C termini), backbone-to-side chain, or side chain-to-
side chain. One of the most popular cyclization methods is by forming the N-to-C (or backbone-
to-backbone) cyclization from the amino to carboxyl terminus using an amide bond. In nature, 
many biologically active cyclic peptides are N-to-C cyclized peptides. Compared to their linear 
counterparts, cyclic peptides are less flexible or more conformationally rigid, which often 
enhances the biological activity of the peptide.26 The rigidity of a cyclic peptide results in a higher 
affinity toward the target receptor compared to the linear counterpart, which is presumably due to 
the decrease in the entropy term of the Gibbs free energy. Moreover, the N-to-C cyclic peptides 
do not have open-ended carboxyl or amino termini that can be subjected to enzymatic degradations 
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by exo- and endopeptidases; therefore, the cyclic peptide is enzymatically more stable than the 
parent linear peptide in the plasma.27 For these reasons, cyclic peptides have been developed 
successfully as therapeutics in the clinic and there are more than 60 approved peptide-derived 
drugs available in the United States and other major markets. Among those, a vast majority are 
derived from natural products such as antimicrobials or human peptide hormones, including widely 
applied cyclic peptides such as oxytocin, octreotide, vasopressin, vancomycin, daptomycin, and 
polymyxinB.28 
It was interesting to find that cyclic HAVN1 and HAVN2 peptides were able to deliver IgG 
mAb while their parent linear HAV6 peptide could not enhance delivery of IgG mAb. HAVN1 is 
a cyclic hexapeptide that has the same sequence as HAV6 while HAVN5 is a cyclic pentapeptide 
with deletion of the C-terminal Ser residue. It is also interesting to find that this Ser deletion in 
HAVN2 still provided BBB modulatory activity similar to that of HAVN1 in the current 
experimental conditions. This finding is consistent with our previous study in which the formation 
of a cyclic HAV peptide called cHAVc3 (cyclo(1,6)Ac-CSHAVC-NH2) had improved modulatory 
activity compared to that of linear HAV peptide.19 It has been shown that HAV6 also did not 
enhance the delivery of 65 kDa albumin using the current conditions; however, HAV6 could 
enhance the delivery of 65 kDa galbumin into the brain when the dose of galbumin was increased 
27 times compared to the current experimental conditions. This suggests that there is an 
improvement in the BBB modulatory activity of cyclic HAVN1 and HAVN2 compared to that of 
linear HAV6, which cannot enhance the delivery of mAb. These results also indicate that cyclic 
pentapeptide HAVN2 can be used as a lead compound for future mutation studies to improve the 
BBB modulatory activity and selectivity. 
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These cadherin peptides interrupt the cadherin-cadherin interactions by binding to the 
extracellular domains of cadherins allowing delivered molecules to pass through the intracellular 
junctions of the BBB. The X-ray structure of C-cadherin showed that cadherin molecules can form 
cis- and trans-interactions with each other in a homotypic fashion.29 The cis-cadherin interactions 
were formed by binding of the EC1 domain from one cadherin molecule to the EC2 domain of 
another cadherin, both of which protrude from the same cell membranes. The trans-cadherin 
interactions were formed by binding between the EC1 domain of a cadherin molecule from one 
cell membranes to the EC1 domain of another cadherin molecule from the opposing cell 
membranes. In this case, a Trp residue at the N-terminus of the first EC1 binds to a hydrophobic 
pocket in the second EC1 from the opposing cell membranes while another Trp the second EC1 
binds to a hydrophobic pocket at the first EC1. This process is called “domain swapping”. Our 
previous NMR studies indicated that HAV peptides bind to the EC1 domain of E-cadherin at the 
interface of cis-cadherin interactions; thus, it is proposed that HAV peptides block cis-cadherin 
interactions to open the paracellular pathways.30 In contrast, ADT peptides bind to the hydrophobic 
pocket involved in the domain-swapping process to block trans-interactions of two opposing  EC1 
domains. These results presumably suggest why ADT peptides have better modulatory activities 
than do HAV peptides. 
We propose that combining the sequences of ADT and HAV peptides could create a more 
potent peptide compared to individual ADT or HAV peptides with the rationale that the new 
peptide can bind to two different binding sites. To test this idea, linear and cyclic ADTHAV 
peptides were synthesized, and the binding properties of cyclic ADTHAV and ADTC5 to the EC1 
domain were determined using SPR, which can evaluate binding kinetics (e.g., binding association 
and dissociation rates) and binding affinity. In this study, different concentrations of the studied 
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peptide were passed through a chip surface modified with immobilized EC1 protein. Prior to the 
binding experiment, it was necessary to check for any non-specific binding (NSB) by injecting the 
peptide to the bare surface of the chip without any protein. In this study, the binding conditions 
have been optimized to minimize or eliminate the non-specific binding of the peptide by finding 
the optimal pH of the running buffer, adding surfactant and blocking agent, and adjusting the salt 
(NaCl) concentration. In this study, NSB was minimized by adding 1% BSA and 0.05% Tween20 
to the running buffer. After optimizing the running conditions, the EC1 protein was immobilized 
on the streptavidin chip via the Streptag I sequence on the N-terminus of the EC1 domain followed 
by injection of various peptide concentrations. The binding results that were observed on the 
sensorgram consisted of three phases: association, dissociation, and regeneration. The obtained 
KD for ADTC5 was 26.8 µM (Figure 4.2), which is in range similar to that of the KD (35 µM) 
determined by NMR upon titration of the 15N-labeled EC1-domain of E-cadherin using 
heteronuclear single quantum coherence spectroscopy (HSQC) experiments. It is interesting to 
find that cyclic ADTHAV has a lower KD (0.114 µM) than that of ADTC5 (35 µM), suggesting 
that ADTHAV cyclic has better binding affinity than ADTC5 to the EC1-domain of E-cadherin.  
Next, the in vivo BBB modulatory activities of linear and cyclic ADTHAV peptides as well as 
ADTC5 to deliver IgG mAb were compared to that of control in C57BL/6 mice. All three peptides 
were effective in delivering IgG mAb into the brain compared to control (Figure 4.5; p < 0.05). 
Cyclic ADTHAV showed a trend of higher activity in delivering IgG mAb compared to linear 
ADTHAV (p = 0.07), while there was no significant difference between cyclic ADTHAV and 
ADTC5 (p = 0.20). There is a significant difference in BBB modulatory activity between cyclic 
ADTHAV and cyclic HAVN2; however, it was not clear whether the different in the activity was 
due to different mechanisms of binding to the EC1 domain. In other words, cyclic ADTHAV 
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potentially has two different binding sites on the EC1 domain to inhibit cis- and trans-cadherin 
interactions due to a sequence combination while cyclic HAVN2 has only one binding site on the 
EC1 domain to inhibit cis-cadherin interactions. The potential binding mechanisms of both 
peptides can be evaluated in the future by NMR experiments.19 It also proposed that a short 
circulation time (15 min) may not be adequate to differentiate BBB modulatory activities of 
ADTC5 and ADTHAV peptides. In the future, we will evaluate the effects of dose and longer 
circulation times to further differentiate the in vivo biological activities of all cyclic peptides that 
were used in the current study. At the same time, the stability of cyclic ADTHAV and ADTC5 in 
the systemic circulation can also be compared because it is predicted that the plasma stability of 
ADTC5 will be lower than that of cyclic ADTHAV; this is due to the instability of the disulfide 
bridge in ADTC5 peptide that could be reduced by glutathione in the blood. 
Because cadherin-mediated cell-cell adhesion is also found in different organs (i.e., liver, 
kidney, heart, spleen, and lung), the effects of cyclic peptides on IgG mAb depositions in other 
organs were determined to evaluate the potential side effects. All peptide-treated groups and the 
control group showed a significantly higher accumulation of IgG mAb in the liver compared to 
spleen, heart, kidney, and lung because most of the metabolic pathways occur in the liver. When 
comparing the control group to all groups treated with HAV peptides (i.e., HAV6, HAVN1, and 
HAVN2), there was no significant difference in depositions of IgG mAb within each specific 
organ. These results suggest that these peptides did not have any effect on the peripheral organs. 
Thus, HAV peptides may have higher specificity in modulating the BBB than the peripheral 
organs. In contrast, cyclic ADTC5 and linear ADTHAV showed a significant increase in IgG mAb 
depositions in heart and kidney compared to control while the cyclic ADTHAV group had a 
significant increase in IgG mAb depositions in lungs, spleen, kidney, and liver. The strong effect 
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of cyclic ADTHAV in peripheral organs was presumably due to its strong binding affinity to the 
EC1 domain of E-cadherins; thus, further studies are needed to evaluate the role of different doses 
in IgG depositions in peripheral organs. 
The duration of time of the BBB opening is an important factor to consider for using cadherin 
peptides to deliver molecules to the brain.  This is because it is dangerous to keep the BBB open 
for a long period of time, allowing unwanted molecules to enter the brain. However, it is necessary 
to keep the opening for an adequate amount of time to allow the delivered molecule to enter the 
brain with the necessary dose. For example, HAV6 has an opening window of less than 1 h to 
allow a small molecule such as R800IRdye and gadopentetic acid (Gd-DTPA) to enter the brain, 
while ADTC5 has a duration of opening between 2 to 4 h for brain delivery of Gd-DTPA.20, 21 
Using a high dose of 65 kDa galbumin, HAV6 peptide can increase the BBB penetration of 
galbumin when they are delivered together; however, a 10-min delay between the delivery of 
HAV6 and galbumin does not allow galbumin to cross the BBB.  Thus, the BBB window of 
opening by HAV6 for a large protein such as galbumin is short (< 10 min). In contrast, the opening 
created by ADTC5 for galbumin is between 10 and 40 min. The results suggest that each peptide 
produces various populations of pore sizes that can collapse in a time-dependent manner, and each 
peptide has a cut-off size of molecules that can be delivered through the BBB. 
4.5. Conclusion 
In this study, we have designed and synthesized novel cyclic peptides that can effectively 
modulate the BBB to enhance the delivery of mAb into the brains of C57BL/6 mice. The new 
peptides were designed based on HAV6 and ADTC5 peptides, which modulate cadherin-cadherin 
interactions in the BBB to improve the delivery of small, medium, and large molecules, including 
proteins. We have shown that cyclic HAVN1 and HAVN2 peptides have better BBB modulatory 
effects than their linear counterpart, HAV6 peptide. Cyclic ADTHAV with a combination of ADT 
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and HAV sequences has better binding affinity to the EC1 domain of E-cadherin than does ADTC5 
peptide. Cyclic ADTHAV can significantly enhance brain delivery of IgG mAb compared to 
control, and it influences the deposition of IgG mAb in peripheral organs while no HAV peptides 
influence the deposition of IgG mAb in these organs. In the future, all cyclic peptides will be 
evaluated in longer circulation times to evaluate their effects in delivering mAb and other proteins 




4.6. Figures and Legends 
 
 
Figure 4.1  A synthetic scheme to make cyclic ADTHAV peptide: (a) Fmoc-deprotection: 
piperidine/DMF (1:4). (b) Coupling reaction in DMF using HCTU, NMM, and Fmoc-amino acids:  
Fmoc-Ala-OH, Fmoc-Ser(Bzl)-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-His(Trt)-OH, Fmoc-
Thr(Bzl)-OH, and Fmoc-Pro-OH. (c) (i) Fmoc-deprotection reaction and (ii) peptide cleavage from 
the resin: TFA/H2O/TIPS (94:3:3) at room temperature and 2-h reaction time. (d) Solution-phase 
cyclization reaction using HATU/DIEA/peptide (2:4:1) in acetonitrile at room temperature and 
24-h reaction time followed by Prep-HPLC. (e) Final hydrogenation reaction for side-chain 





Figure 4.2  SPR sensorgrams of binding between cyclic ADTHAV peptide and the EC1 protein 
immobilized onto streptavidin chips using the OpenSPR Nicoya instrument. Sensorgrams were 



















Figure 4.3  SPR sensorgrams of binding between cyclic ADTC5 peptide and the EC1 protein 
immobilized onto streptavidin chips using the OpenSPR Nicoya instrument. Sensorgrams were 
recorded using increasing amounts of ADTC5 (6.25 µM – 50 µM) in running buffer during the 
association phase.  












Figure 4.4  (A) The levels of brain depositions of IRdye800CW-IgG mAb were qualitatively 
shown by NIRF imaging after administration of IgG mAb (21.6 nmol/kg) alone as a control or 
along linear HAV6, cyclic HAVN1, or cyclic HAVN2 (13 µmol/kg) in C57BL/6 mice. (B) 
IRdye800CW-IgG mAb brain depositions were determined quantitatively using NIRF imaging in 
pmol/g brain after delivery of IgG mAb when delivered alone (21.6 nmol/kg) or delivered with 
HAV6, HAVN1, or HAVN2 (13 µmol/kg) in C57BL/6 mice. The asterisk symbol (*) was used to 
designate a significant difference in HAVN1- or HAVN2-treated groups compared to control with 







Figure 4.5  (A) The qualitative brain depositions of IRdye800CW-IgG mAb shown as NIRF 
images after its i.v. administration alone (21.6 nmol/kg) as a control and together with cyclic 
ADTC5, linear ADTHAV, or cyclic ADTHAV (13 µmol/kg) in C57BL/6 mice. (B) Quantitative 
determination of IRdye800CW-IgG mAb brain depositions in pmol/g brain after its administration 
(21.6 nmol/kg) without peptide as a control group or in the presence of ADTC5, linear ADTHAV, 
or cyclic ADTHAV (13 µmol/kg) in C57BL/6 mice. The asterisk (*) indicates a significant 
difference in cyclic ADTC5-, linear ADTHAV-, or cyclic ADTHAV-treated groups compared to 









Figure 4.6  The effects of linear HAV6, cyclic HAVN1, and cyclic HAVN2 peptides on the 
peripheral organ depositions of the IRdye800CW-IgG mAb in heart, lung, kidney, spleen, and 
liver determined using NIRF signal intensity (A) qualitatively and (B) quantitatively in absorption 
unit (A.U.). The IgG mAb depositions were measured by the total NIRF image intensity in each 
organ. There is no significant difference in the IgG mAb signal intensities for each organ when 
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comparing the control group and peptide-treated group with p > 0.05. Error bars show the mean ± 





Figure 4.7  The effects of cyclic ADTC5, linear ADTHAV, and cyclic ADTHAV peptides on the 
peripheral organ deposition of the IRdye800CW-IgG mAb in heart, lung, kidney, spleen, and liver 
determined using NIRF signal intensity (A) qualitatively and (B) quantitatively in absorption unit 
(A.U.). The IgG mAb depositions were measured by the total NIRF image intensity in each organ. 
There are significance differences in the IgG mAb signal intensities for kidney and heart of 
ADTC5- or linear ADTHAV-treated mice compared to control (p > 0.05). There are significant 
differences in the IgG mAb signal in all five organs from the cyclic ADTHAV-group compared to 
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5.1 Summary and Conclusions 
The overall objective of this project was to enhance the brain delivery of peptides and proteins 
in mouse and rat models. The objectives of this project were to (a) develop methods to detect the 
delivery of peptides and proteins into the brains; (b) modulate the blood-brain barrier (BBB) for 
brain delivery of peptides and proteins using cadherin peptides; and (c) design and evaluate new 
cyclic cadherin peptides to improve BBB modulatory activity to deliver proteins into the brain. 
The BBB acts as a physical and enzymatical barrier to delivery of foreign molecules, including 
drugs, to the brain; therefore, this makes the development of diagnostics and drugs for brain 
diseases challenging. 
In the second chapter, we found that BBB-modulating peptides (i.e., HAV6, cHAVc3, and 
ADTC5) enhance the delivery of various molecules such as a 65 kDa galbumin and peptides (i.e., 
cIBR7, IRdye800cw-cLABL) in both mice and rats. These BBB-modulating peptides significantly 
enhanced the brain delivery of 65 kDa galbumin compared to control in Balb/c mice as quantified 
by magnetic resonance imaging (MRI). A 10-min pretreatment with ADTC5 peptide significantly 
increased brain delivery of galbumin; however, no enhancement was observed after a 10-min 
pretreatment with HAV6. There was no enhancement of galbumin deposition following 40-min 
pretreatment with ADTC5 or HAV6, suggesting a short duration of the BBB opening for large 
molecules. Next, near IR fluorescence (NIRF) was used to detect the enhanced delivery of 
IRdye800cw-cLABL peptide in the presence of ADTC5 peptide, which resulted in a 3.5-fold 
improved brain delivery compared to control in Balb/c mice. Finally, as a proof of study, a non-
labeling method, LC-MS/MS, was used to evaluate the BBB modulator activity of ADTC5 to 
deliver cIBR7 peptide in vivo using Sprague-Dawley rats. LC-MS/MS was developed and 
validated for accuracy, precision, stability and linear calibration curves. Extraction procedures 
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were optimized for efficient extraction of peptides from the brain homogenates. Deposition of 
cIBR7 peptide in the presence of ADTC5 and absence (controls) were quantified and showed that 
ADTC5 peptide as a BBB modulator enhanced the delivery of cIBR7 peptide into rat brain about 
4-fold compared to control. Overall, we showed that ADTC5 was capable of modulating the BBB 
to enhance peptide and protein delivery to the brain using both labelled and non-labeled 
quantifying methods. 
Currently, biologics or protein drugs have drawn attention to inventing new medicines, mainly 
for brain diseases because limited effective treatments exist for many brain conditions, including 
brain tumors, autoimmune diseases, neurodegenerative diseases, infectious diseases, and genetic 
disorders. Although many biological drugs have been developed and are already on the market, 
there are no successful biological drugs targeting neurological conditions and brain diseases such 
as, Alzheimer’s, Parkinson’s and multiple sclerosis. This is mainly due to the inability to deliver 
those drugs to the brain due to their large molecular size. In our previous study, we successfully 
delivered galbumin (65 kDa) to the brain by modulating the BBB. The next goal of this work is to 
evaluate and quantitatively determine the delivery of large proteins into the brain using cadherin 
peptides, ADTC5, and HAV6. 
In Chapter 3, we have compared two BBB modulator peptides (i.e., ADTC5 and HAV6) in 
improving the delivery of different sized proteins from 15 kDa to 220 kDa in C57BL/6 mice. 
Lysozyme (15 kDa), albumin (65 kDa), IgG mAb (150 kDa), and fibronectin (220 kDa) were 
labeled with IRdye800CW to be quantified after the in vivo delivery using NIRF imaging.  A novel 
NIRF quantifying method was developed and validated for accuracy, precision, stability and linear 
calibration curves according to the FDA guidelines. With our in vivo studies, it showed that 
ADTC5 peptide significantly enhanced brain delivery of lysozyme, albumin and IgG mAb but not 
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fibronectin compared to controls. In contrast, HAV6 peptide significantly enhanced the brain 
delivery of lysozyme but not albumin and IgG mAb. Thus, there is a cut-off size of proteins that 
can be delivered by each peptide. Overall, we showed that ADTC5 is a better BBB modulator than 
HAV6 in delivering various sizes of proteins into the brain.  
Since HAV and ADT peptides showed different binding sites in EC1 of the cadherin protein 
in our previous NMR studies, it was interesting to design novel peptides with a combination 
sequence targeting for a better modulatory effect. Moreover, it is well known that cyclic peptides 
have shown a higher stability and better biological activity than their linear counterparts. The main 
goal in Chapter 3 was to design novel cyclic peptides and evaluate their activity in vitro and in 
vivo for the BBB modulation. While HAV6 is a linear peptide and ADTC5 is a disulfide bridged 
cyclic peptide, both peptides have shown promising BBB-modulating activity to improve brain 
delivery of various molecules. We have designed and synthesized cyclic and linear ADTHAV 
peptides derived from both sequences of ADTC5 and HAV6 peptides. We also designed and 
synthesized cyclic HAVN1 and HAVN2 peptides that are C-to-N cyclized peptides derived from 
linear HAV6 peptide. It is hypothesized that by combining the two sequences and forming N-to-
C terminal cyclization, the resulting peptides will be more stable and have a higher BBB 
modulatory effect. All the novel peptides were compared with ADTC5, HAV6, and control (with 
no peptide to modulate the BBB) for delivery of an IRdye800CW IgG mAb to C57BL mice. It is 
interesting to show that both HAVN1 and HAVN2 peptides showed higher accumulations of IgG 
mAb in mice brains compared to HAV6 and control. In Chapter 3 we have shown that there is no 
significant difference between HAV6 and control brains for deposition of IRdye800cw-IgG mAb; 
however, after cyclizing the HAV6 peptide using N-to-C terminal cyclization there was a 
significant difference in brain delivery of mAb by either HAVN1 or HAVN2 compared to control. 
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Moreover, cyclic and linear ADTHAV peptides showed higher deposition of IRdye800cw-IgG 
mAb, but there was no significance difference compared to ADTC5. It is assumed that the current 
condition of 15-minute circulation time was not adequate to detect significant differences among 
the cyclic peptides. Therefore, longer circulation times will be investigated to differentiate the 
activities of the cyclic peptides. In addition, more experiments will be carried out to evaluate the 
stability and efficacy of cyclic ADTHAV in the future.  
5.2 Future Directions 
5.2.1 Brain Delivery of Neuroregenerative Molecules 
Neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer’s disease (AD) 
affect people of all ages and result in progressive degeneration and death of neurons. In MS 
patients, the myelin sheaths of the neuronal axons are attacked and damaged by their own immune 
cells.1,2 Repairing and protecting myelin is one of the approaches in treating MS. Unfortunately, 
while all of the available drugs are capable of preventing further injury to nerves and axons by 
suppressing the immune response, none of the available drugs can repair the neuronal damage that 
has already occurred. In AD, neuronal degeneration relates to accumulation of extracellular 
amyloid plaques and intracellular neurofibrillary tangles in the brain.3,4 Even though several 
antibody treatments targeting amyloid beta have shown some promising results for treating AD, 
most of them have failed clinically due to ineffectiveness in delivering them to the brain.5,6 
One way to reverse the neuronal damage in neurodegenerative diseases is to deliver 
neuroregenerative molecules such as brain-derived neurotrophic factor (BDNF),7-9 nerve growth 
factor (NGF),10 or insulin-like growth factor 1 (IGF-1)11 to the CNS. In our previous studies we 
have successfully shown that we can enhance the delivery of various sizes of proteins up to 
monoclonal antibodies (150 kDa) to healthy mice using ADTC5 as the BBB modulator. In future 
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studies, BDNF can be delivered to MS and AD mouse models using ADTC5 or any of the novel 
peptides as the BBB modulator. With our promising results for enhanced antibody delivery in 
previous studies, an effective BDNF delivery is expected and it will induce the remyelination and 
neuroregeneration. The results can be evaluated according to (a) disease scores, (b) behavior, (c) 
physical appearance, (d) pathology of neuroregeneration/repair, and (e) mechanism of 
neuroregeneration in the brain by detecting upregulation of signal proteins induced by BDNF 
delivery. 
5.2.2 Brain Delivery of Antibody Drugs to Treat Brain Tumors  
Because the BBB is a barrier to many developed drugs, our BBB-modulating peptides have 
increased brain delivery by modulating the cadherins in the intracellular junction. In Chapters 2, 
3, and 4 we have shown that our BBB-modulating peptides can improve the delivery of various 
molecules, including peptides, proteins, and monoclonal antibodies.  
Among many biological drugs such as monoclonal antibodies (mAbs), Fab fragments, and 
mAb-drug conjugates such as avastin (bevacizumab), herceptin, kadcyla, and mylotarg have been 
used successfully to treat tumors outside of the brain. But none of them can be used to treat brain 
tumors (e.g., glioblastoma, medulloblastoma) due to their inability to cross the BBB and enter the 
brain. Therefore, our BBB modulating peptides, ADTC5, and novel ADTHAV peptides could be 
used to improve the brain delivery of anti-tumor drugs to improve its paracellular permeability to 
the brain. A mixture of the BBB-modulating peptide and an unlabeled or labeled antibody drug 
can be administered intravenously (i.v.) in normal or brain-tumor mouse models. 
5.2.3 Novel Peptides for Brain Delivery of Proteins 
In Chapter 3, we have shown that ADTC5 can improve the brain delivery of various proteins 
up the size of a monoclonal antibody (150 kDa) with a cut-off size of 220 kDa using current 
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conditions—peptide (13 µmol/kg), protein (21.6 nmol/kg), and 15-min circulation time. In Chapter 
4, we have designed and synthesized novel cyclic peptides with the hypothesis that, by combining 
the two sequences of ADTC5 and HAV6 peptides (ADTHAV peptides) and cyclizing through N 
to C terminal cyclization, better modulatory peptides with higher stability would result. Even 
though we see higher modulatory effects for the cyclic peptides HAVN1 and HAVN2 compared 
to their linear counterpart HAV6, there was no significant difference between the ADTHAV 
peptides and ADTC5 peptide. It is assumed that the current cyclization time (15 min) was not 
sufficient to show a significant effect on stability. It can be hypothesized that the deposition of 
protein in the brain is correlated to the time of circulation. Therefore, increasing the circulation 
time should eventually show a significant difference in protein deposition with different peptides. 
Thus, the effects of circulation time on brain deposition can be optimized to find the optimal 
circulation time. Also, in vitro plasma stability experiments can be done with the peptides to 
evaluate their half-lives and other kinetic parameters.  
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